0001683168-20-004267.txt : 20201211 0001683168-20-004267.hdr.sgml : 20201211 20201211164733 ACCESSION NUMBER: 0001683168-20-004267 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20201031 FILED AS OF DATE: 20201211 DATE AS OF CHANGE: 20201211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PharmaCyte Biotech, Inc. CENTRAL INDEX KEY: 0001157075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621772151 STATE OF INCORPORATION: NV FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-68008 FILM NUMBER: 201383997 BUSINESS ADDRESS: STREET 1: 23046 AVENIDA DE LA CARLOTA, SUITE 600 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 BUSINESS PHONE: (917) 595.2850 MAIL ADDRESS: STREET 1: 23046 AVENIDA DE LA CARLOTA, SUITE 600 CITY: LAGUNA HILLS STATE: CA ZIP: 92653 FORMER COMPANY: FORMER CONFORMED NAME: NUVILEX, INC. DATE OF NAME CHANGE: 20090324 FORMER COMPANY: FORMER CONFORMED NAME: EFOODSAFETY COM INC DATE OF NAME CHANGE: 20010808 10-Q 1 pharmacyte_10q-103120.htm QUARTERLY REPORT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number 333-68008

PHARMACYTE BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Nevada	62-1772151
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

23046 Avenida de la Carlota, Suite 600, Laguna Hills, CA 92653

(Address of principal executive offices)

(917) 595-2850

(Registrant’s telephone number, including area code)


Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer o	Accelerated filer o
	Non-accelerated filer x	Smaller reporting company x
	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of December 11, 2020, the registrant had 2,334,810,405 outstanding shares of common stock, with a par value of $0.0001 per share.

PHARMACYTE BIOTECH, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2020

		Page
PART I.	FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (Unaudited)

	Condensed Consolidated Balance Sheets as of October 31, 2020 and April 30, 2020 (Unaudited)	3

	Condensed Consolidated Statements of Operations for the Three and Six Months Ended October 31, 2020 and 2019 (Unaudited)	4

	Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended October 31, 2020 and 2019 (Unaudited)	5

	Condensed Consolidated Statements of Stockholders’ Equity for the Six Months Ended October 31, 2020 and 2019 (Unaudited)	6

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended October 31, 2020 and 2019 (Unaudited)	7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31

Item 4.	Controls and Procedures	31

PART II.	OTHER INFORMATION	33

Item 1.	Legal Proceedings	33

Item 1A.	Risk Factors	33

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33

Item 3.	Defaults Upon Senior Securities	34

Item 4.	Mine Safety Disclosures	34

Item 5.	Other Information	34

Item 6.	Exhibits	34

	Signatures	35

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

PHARMACYTE BIOTECH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	October 31, 2020			April 30, 2020

ASSETS
Current assets:
Cash	$	3,717,404		$	894,861
Prepaid expenses and other current assets		94,963			142,785
Total current assets		3,812,367			1,037,646

Other assets:
Intangibles		3,549,427			3,549,427
Investment in SG Austria		1,572,193			1,572,193
Other assets		7,372			7,372
Total other assets		5,128,992			5,128,992

Total Assets	$	8,941,359		$	6,166,638

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	80,118		$	185,842
Accrued expenses		509,422			816,638
Current portion of Small Business Administration – Paycheck Protection Program loan		54,110			28,918
Total current liabilities		643,650			1,031,398

Long-term liabilities, less current portion:
Small Business Administration – Paycheck Protection Program loan		21,090			46,282

Total Liabilities		664,740			1,077,680

Commitments and Contingencies (Notes 7 and 9)

Stockholders' equity:
Common stock, authorized: 2,490,000,000 shares, $0.0001 par value; 2,334,810,405 and 1,638,637,839 shares issued and outstanding as of October 31, 2020 and April 30, 2020, respectively		233,482			163,864
Additional paid-in capital		113,757,416			108,805,062
Accumulated deficit		(105,692,395	)		(103,858,259	)
Accumulated other comprehensive loss		(21,884	)		(21,709	)
Total stockholders' equity		8,276,619			5,088,958

Total Liabilities and Stockholders' Equity	$	8,941,359		$	6,166,638

See accompanying Notes to Condensed Consolidated Financial Statements.

PHARMACYTE BIOTECH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended October 31,						Six Months Ended October 31,
	2020			2019			2020			2019

Revenue	$	–		$	–		$	–		$	–

Operating expenses:
Research and development costs		151,314			17,940			421,888			90,270
Compensation expense		552,462			446,146			831,432			899,340
Director fees		69,317			82,854			141,341			158,496
Legal and professional		88,412			115,454			230,168			225,611
General and administrative		88,010			404,728			206,362			827,480
Total operating expenses		949,515			1,067,122			1,831,191			2,201,197

Loss from operations		(949,515	)		(1,067,122	)		(1,831,191	)		(2,201,197	)

Other expenses:
Interest expense		(677	)		–			(1,757	)		–
Other expense		–			–			(1,188	)		–
Total other expenses		(677	)		–			(2,945	)		–

Net loss	$	(950,192	)	$	(1,067,122	)	$	(1,834,136	)	$	(2,201,197	)

Basic and diluted loss per share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average shares outstanding basic and diluted		2,309,218,013			1,325,086,933			1,993,895,090			1,267,696,383

See accompanying Notes to Condensed Consolidated Financial Statements.

PHARMACYTE BIOTECH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

	Three Months Ended October 31,						Six Months Ended October 31,
	2020			2019			2020			2019

Net Loss	$	(950,192	)	$	(1,067,122	)	$	(1,834,136	)	$	(2,201,197	)
Other comprehensive income (loss):
Foreign currency translation		2,852			(66	)		(175	)		(6,928	)
Other comprehensive income (loss)		2,852			(66	)		(175	)		(6,928	)
Comprehensive loss	$	(947,340	)	$	(1,067,188	)	$	(1,834,311	)	$	(2,208,125	)

See accompanying Notes to Condensed Consolidated Financial Statements.

PHARMACYTE BIOTECH, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

SIX MONTHS ENDED OCTOBER 31, 2020 AND 2019

(UNAUDITED)

	Series A Preferred Stock				Common stock				Additional Paid-in		Accumulated			Other Comprehensive Income			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			(Loss)			Equity

Balance, April 30, 2020		–	$	–		1,638,637,839	$	163,864	$	108,805,062	$	(103,858,259	)	$	(21,709	)	$	5,088,958

Shares issued for compensation		–		–		–		–		67,320		–			–			67,320
Shares issued for services		–		–		2,500,000		250		40,300		–			–			40,550
Shares issued for cash, net of issuance costs of $198,150		–		–		234,005,899		23,401		1,833,996		–			–			1,857,397
Stock-based compensation - options		–		–		–		–		72,317		–			–			72,317
Foreign currency translation adjustment		–		–		–		–		–		–			2,677			2,677
Net loss		–		–		–		–		–		(883,944	)		–			(883,944	)
Balance, July 31, 2020		–		–		1,875,143,738		187,515		110,818,995		(104,742,203	)		(19,032	)		6,245,275

Shares issued for compensation		–		–		–		–		67,320		–			–			67,320
Shares issued for services		–		–		1,000,000		100		19,059		–			–			19,159
Shares issued for cash, net of issuances costs of $278,150		–		–		458,666,667		45,867		2,795,983		–			–			2,841,850
Stock-based compensation - options		–		–		–		–		56,059		–			–			56,059
Foreign currency translation adjustment		–		–		–		–		–		–			(2,852	)		(2,852	)
Net loss		–		–		–		–		–		(950,192	)		–			(950,192	)
Balance, October 31, 2020		–	$	–		2,334,810,405	$	233,482	$	113,757,416	$	(105,692,395	)	$	(21,884	)	$	8,276,619

Balance, April 30, 2019		–	$	–		1,186,004,505	$	118,600	$	104,966,158	$	(100,031,371	)	$	(13,842	)	$	5,039,545

Shares issued for compensation		–		–		–		–		104,726		–			–			104,726
Shares issued for services		–		–		5,500,000		550		311,266		–			–			311,816
Shares issued for cash, net of issuance costs of $70,000		–		–		66,666,667		6,667		551,333		–			–			558,000
Stock-based compensation - options		–		–		–		–		126,325		–			–			126,325
Foreign currency translation adjustment		–		–		–		–		–		–			(6,862	)		(6,862	)
Net loss		–		–		–		–		–		(1,134,075	)		–			(1,134,075	)
Balance, July 31, 2019		–		–		1,258,171,172		125,817		106,059,808		(101,165,446	)		(20,704	)		4,999,475

Shares issued for compensation		–		–		–		–		104,727		–			–			104,727
Shares issued for services		–		–		3,700,000		370		73,183		–			–			73,553
Shares issued for cash, net of issuances costs of $24,500		1		–		70,000,000		7,000		318,501		–			–			325,501
Stock-based compensation - options		–		–		–		–		98,409		–			–			98,409
Foreign currency translation adjustment		–		–		–		–		–		–			(66	)		(66	)
Net loss		–		–		–		–		–		(1,067,122	)		–			(1,067,122	)
Balance, October 31, 2019		1	$	–		1,331,871,172	$	133,187	$	106,654,628	$	(102,232,568	)	$	(20,770	)	$	4,534,477

See accompanying Notes to Condensed Consolidated Financial Statements.

PHARMACYTE BIOTECH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended October 31,
	2020			2019

Cash flows from operating activities:
Net loss	$	(1,834,136	)	$	(2,201,197	)
Adjustments to reconcile net loss to net cash used in operating activities:
Shares issued for services		59,709			385,369
Shares issued for compensation		134,640			209,453
Stock-based compensation – options		128,376			224,734
Change in assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets		47,822			(26,128	)
Increase (decrease) in accounts payable		(105,725	)		42,697
Increase (decrease) in accrued expenses		(232,139	)		18,307
Net cash used in operating activities		(1,801,453	)		(1,346,765	)

Cash flows from investing activities:
Net cash provided by (used in) investing activities		–			–

Cash flows from financing activities:
Payment of insurance financing loan		(75,076	)		–
Proceeds from sale of Series A Preferred Stock		–			1
Proceeds from sale of common stock, net of issuance costs		4,699,247			883,500
Net cash provided by financing activities		4,624,171			883,501

Effect of currency rate exchange on cash		(175	)		(6,928	)

Net increase (decrease) in cash		2,822,543			(470,192	)

Cash at beginning of the period		894,861			515,253
Cash at end of the period	$	3,717,404		$	45,061
Supplemental disclosure of cash flows information:
Cash paid during the periods for income taxes	$	800		$	800
Cash paid during the periods for interest	$	1,757		$	–

See accompanying Notes to Condensed Consolidated Financial Statements.

PHARMACYTE BIOTECH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 – NATURE OF BUSINESS

Overview

PharmaCyte Biotech, Inc. (“Company”) is a biotechnology company focused on developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box^®.” The Cell-in-a-Box^®technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, pancreatic cancer (“LAPC”), and Type 1 and insulin dependent Type 2 diabetes will be developed.

The Company is developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer prodrug into its cancer-killing form, encapsulating those cells using the Cell-in-a-Box^® technology and placing those capsules in the body as close as possible to the tumor. In this way, the Company believes that when the cancer prodrug is administered to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient’s tumor may be optimized.

The Company is also examining ways to exploit the benefits of the Cell-in-a-Box^® technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant; these constituents are of the class of compounds known as “cannabinoids.” Until the U.S. Food and Drug Administration (“FDA”) allows the Company to commence the clinical trial involving LAPC described in the Company’s recently filed Investigational New Drug Application (“IND”) for which the FDA has placed a clinical hold, the Company is not spending any further resources developing this program.

In addition, the Company is developing a therapy to delay the production and accumulation of malignant ascites fluid that results from many types of abdominal cancerous tumors. Malignant ascites fluid is secreted by abdominal cancerous tumors into the abdomen after the tumors have reached a certain stage of growth. This fluid contains cancer cells that can seed and form new tumors throughout the abdomen. This fluid accumulates in the abdominal cavity, causing swelling of the abdomen, severe breathing difficulties and extreme pain.

The Company is using its therapy for pancreatic cancer to determine if it can prevent or delay the production and accumulation of malignant ascites fluid. As with the Company’s Cannabis program, until the FDA allows it to commence the clinical trial involving LAPC described in its recently filed IND for which the FDA has placed a clinical hold, the Company is not spending any further resources developing this program.

The Company is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. The Company’s diabetes therapy consists of encapsulated genetically modified human liver cells and insulin-producing stem cells. The encapsulation for each type of cell will be done using the Cell-in-a-Box^® technology. Implanting these cells in the body is designed to function as a bio-artificial pancreas for purposes of insulin production. As with the two previous programs, the Company is not spending any further resources developing this program until the FDA allows the Company to commence the clinical trial involving LAPC described in its recently filed IND for which the FDA has placed a clinical hold. However, related work at the University of Technology, Sydney (“UTS”) on the Melligen cells continues. Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body.

Finally, the Company has licensed (“Hai Kang License Agreement”) from Hai Kang Life Corporation (“Hai Kang”) the right to certain technology owned or controlled by Hai Kang related to SARS-Cov2 COVID-19 diagnostic kits (“Kits”). On November 19, 2020, the Company sent Hai Kang a letter terminating the Hai Kang License Agreement. See Note 13- Subsequent Events.

Clinical Hold

On September 1, 2020, the Company submitted an IND to the FDA for a planned Phase 2b clinical trial in LAPC. Shortly thereafter, the Company received Information Requests from the FDA related to the IND. The Company timely responded to all information requests.

On October 1, 2020, the Company received notice that the FDA had placed the IND on clinical hold.

On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted.

In order to lift the clinical hold, the FDA has informed the Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several topics, including data, manufacturing information and product release specifications.

In addition, the FDA requested that several items not related to the clinical hold be addressed through the submission of an IND amendment. Specifically, the FDA requested that the Company perform qualification studies for the drug substance filling step to ensure that the product remains sterile and stable during the filling process. The FDA also requested additional information, discussion and clarification on several other topics.

There has been no further communication with the FDA regarding the clinical hold.

The Company has assembled a scientific team to address the FDA requests related to the clinical hold.

See Management’s Discussion and Analysis of Financial Condition and Results of Operations-Clinical Hold for a further discussion of the clinical hold.

Impact of the COVID-19 Pandemic on the Company’s Operations

The coronavirus SARS-Cov2 pandemic (“COVID-19”) is causing significant, industry-wide delays in clinical trials. Although the Company is not yet in a clinical trial, the Company has filed an IND with the FDA to commence a clinical trial in LAPC. While the IND has been placed on clinical hold by the FDA, the Company has assessed the impact of COVID-19 on its operations. Currently, many clinical trials are being delayed due to COVID-19. There are numerous reasons for these delays. For example, patients have shown a reluctance to enroll or continue in a clinical trial due to fear of exposure to COVID-19 when they are in a hospital or doctor’s office. There are local, regional and state-wide orders and regulations restricting usual normal activity by people. These discourage and interfere with patient visits to a doctor’s office if the visit is not COVID-19 related. Healthcare providers and health systems are shifting their resources away from clinical trials toward the care of COVID-19 patients. The FDA and other healthcare providers are making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to COVID-19. As of the date of this Report on Form 10-Q (“Report”), the COVID-19 pandemic has had an impact upon the Company’s operations, although the Company believes that impact is not material. The impact primarily relates to delays in tasks associated with the preparation of the Company’s response to the clinical hold, including all preclinical studies. There may be further delays in generating responses to the requests from the FDA related to the clinical hold.

As a result of the COVID-19 pandemic, commencement of the Company’s planned clinical trial to treat LAPC may be delayed beyond the lifting of the clinical hold should that occur. Also, enrollment may be difficult for the reasons discussed above. In addition, after enrollment in the trial, if patients contract COVID-19 during their participation in the trial or are subject to isolation or shelter in place restrictions, this may cause them to drop out of our trial, miss scheduled therapy appointments or follow-up visits or otherwise fail to follow the trial protocol. If patients are unable to follow the trial protocol or if the trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the trial may be compromised or not be accepted by the FDA. This could further adversely impact or delay the Company’s clinical development program.

It is highly speculative in projecting the effects of COVID-19 on the Company’s clinical development program and the Company generally. The effects of COVID-19 quickly and dramatically change over time. Its evolution is difficult to predict, and no one is able to say with certainty when the pandemic will subside.

Company Background

The Company is a Nevada corporation incorporated in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The restructuring resulted in the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer and diabetes. In January 2015, the Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) Bio Blue Bird AG; (ii) PharmaCyte Biotech Europe Limited; (iii) PharmaCyte Biotech Australia Pty. Ltd.; and (iv) Viridis Biotech, Inc. and are prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“Commission”). Intercompany balances and transactions are eliminated. The Company’s 14.5% investment in SG Austria is presented on the cost method of accounting.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates these estimates including those related to fair values of financial instruments, intangible assets, fair value of stock-based awards, income taxes and contingent liabilities, among others. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s Condensed Consolidated Financial Statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s condensed consolidated financial position and results of operations.

Intangible Assets

The Financial Accounting Standards Board ("FASB") standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year.

The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box^®technology for $1,549,427 and the diabetes license for $2,000,000 for an aggregate total of $3,549,427.

These intangible assets have an indefinite life; therefore, they are not amortizable.

The Company concluded that there was no impairment of the carrying value of the intangibles for the six months ended October 31, 2020 and 2019.

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment was identified or recorded during the six months ended October 31, 2020 and 2019.

Fair Value of Financial Instruments

For certain of the Company’s non-derivative financial instruments, including cash, accounts payable and accrued expenses, the carrying amount approximates fair value due to the short-term maturities of these instruments.

Accounting Standards Codification ("ASC") Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the condensed consolidated balance sheets for current liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

•

Level 1. Observable inputs such as quoted prices in active markets;

•

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Income Taxes

Deferred taxes are calculated using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. The Company believes the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based on, among other things, an estimate of future taxable income in the U.S. and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against the Company’s net deferred income tax assets, the Company considers all available evidence, both positive and negative. Consistent with the Company’s policy, and because of the Company’s history of operating losses, the Company does not currently recognize the benefit of all its deferred tax assets, including tax loss carry forwards, which may be used to offset future taxable income. The Company continually assesses its ability to generate sufficient taxable income during future periods in which deferred tax assets may be realized. When the Company believes it is more-likely-than-not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in the Condensed Consolidated Statements of Operations.

The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more-likely-than-not to be sustained upon examination. Step two, measurement, is addressed only if a position is more-likely-than-not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more-likely-than-not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more-likely-than-not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more-likely-than-not standard is met, the issue is resolved with the taxing authority or the statute of limitations expires. Positions previously recognized are derecognized when the Company subsequently determines the position no longer is more-likely-than-not to be sustained. Evaluation of tax positions, their technical merits and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.

On March 27, 2020, Congress enacted the “Coronavirus Aid, Relief and Economic Security ("CARES") Act” to provide certain relief as a result of COVID-19. The Company maintains a full valuation allowance on its U.S. net deferred tax assets. Deferred tax asset remeasurement (tax expense) was offset by a net decrease in valuation allowance, that resulted in no impact on the Company's income tax expense. Therefore, the Company does not expect the provisions in the CARES Act will impact the Company’s Condensed Consolidated Financial Statements.

Research and Development

Research and development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in R&D and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established.

R&D expenses for the three and six months ended October 31, 2020 were $151,314 and $421,888, respectively, and for the three and six months ended October 31, 2019 were $17,940 and $90,270, respectively.

Stock-Based Compensation

The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future.

Concentration of Credit Risk

The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at a financial institution located in California. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. Uninsured balances aggregated approximately $3,439,000 and $618,000 at October 31, 2020 and April 30, 2020, respectively. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit risk on cash.

Foreign Currency Translation

The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters. All assets and liabilities of the Company’s foreign subsidiaries are translated at period-end exchange rates, while revenue and expenses are translated at average exchange rates prevailing during the period. Adjustments for foreign currency translation fluctuations are excluded from net loss and are included in other comprehensive loss. Gains and losses on short-term intercompany foreign currency transactions are recognized as incurred.

Going Concern

The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern; however, the following conditions raise substantial doubt about the Company's ability to do so. As of October 31, 2020, the Company has an accumulated deficit of $105,692,395 and incurred a net loss for the six months ended October 31, 2020 of $1,834,136. The Company requires substantial additional capital to finance its planned business operations and expects to incur operating losses in future periods due to the expenses related to the Company’s core businesses. The Company has not realized any revenue since it commenced doing business in the biotechnology sector, and there can be no assurance that it will be successful in generating revenues in the future in this sector. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

For the six months ended October 31, 2020, funding was provided by investors to maintain and expand the Company’s operations. Sales of the Company’s common stock were made under an operative Form S-3 (“S-3”) allowing for offerings of up to $50 million dollars in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (“Securities Act”) or transactions structured as a public offering of a distinct block or blocks of the shares of the Company’s common stock. During the six months ended October 31, 2020, the Company continued to acquire funds through the Company’s S-3 pursuant to which the placement agent sells shares of common stock “at-the-market” in a program which is structured to provide up to $25 million to the Company less certain commissions pursuant to the S-3.

On August 13, 2020, the Company no longer met the eligibility requirements to use the S-3 to raise capital, and the Company ceased to use the S-3 to raise capital after that date. From May 1, 2020 through August 13, 2020 the Company raised capital of approximately $4.7 million in Block Trade transactions and “at-the-market” transactions.

Management determined that its plans to raise additional capital alleviate substantial doubt about the Company’s ability to continue as a going concern. The Company believes the cash on hand, the potential sales of unregistered shares of its common stock and any public offerings of common stock in which the Company may engage in will provide sufficient capital to meet the Company’s capital requirements and to fund the Company’s operations through December 31, 2021.

Recent Accounting Pronouncements

ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), was issued in June 2016. Under ASU 2016-13, existing guidance on reporting credit losses for trade and other receivables and available for sale debt securities will be replaced with a new forward-looking "expected loss" model that generally will result in the earlier recognition of allowances for losses. The Company’s adoption of ASU 2016-13 during the quarter ended July 31, 2020 did not result in an impact on the Company’s Condensed Consolidated Financial Statements. As part of the Company’s continuing assessment of the adequacy of AU 2016-13, there are no factors to be considered at this time, as the Company does not have an allowance for credit losses.

ASU No. 2019-12, Simplifying the Accounting for Income Taxes ("ASU 2019-12"), was issued in December 2019. Under ASU 2019-12, the accounting for income taxes is simplified by eliminating certain exceptions and implementing additional requirements which result in a more consistent application of ASC 740. The Company is currently in the process of evaluating the impact of adopting ASU 2019-12 in 2021, but it does not expect it to have a material impact on the Company’s Condensed Consolidated Financial Statements.

NOTE 3 – ACCRUED EXPENSES

Accrued expenses at October 31, 2020 and April 30, 2020 are summarized below:

	October 31, 2020		April 30, 2020
Payroll related costs	$	462,781	$	435,577
Director and Officer insurance financing		38,168		113,245
Other		8,473		267,816
Total	$	509,422	$	816,638

The Company financed the Director and Officer insurance policy. The term of the policy is from March 8, 2020 through March 8, 2021. The financing agreement has an interest rate of 4.25% per annum and requires eight monthly payments of $12,806. The unpaid balances as of October 31, 2020 and April 30, 2020 are $38,168 and $113,245, respectively, which are included in accrued expenses.

NOTE 4 – SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM

On March 27, 2020, the CARES Act was enacted to provide financial aid to family and businesses impacted by COVID-19. The Company participated in the CARES Act, and on April 15, 2020, the Company entered into a note payable with a bank under the Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”) loan in the amount of $75,200. This loan payable matures on April 15, 2022 with a fixed interest rate of 1% per annum with interest deferred for six months. The PPP loan has an initial term of two years, is unsecured and guaranteed by the SBA. Under the terms of the PPP loan, the Company may apply for forgiveness of the amount due on the PPP loan. The Company used the proceeds from the PPP loan for qualifying expenses as defined in the PPP. The Company intends to apply for forgiveness of the PPP loan in accordance with the terms of the CARES Act. However, the Company cannot assure at this time that the PPP loan will be forgiven partially or in full. The outstanding PPP loan balance as of October 31, 2020 and April 30, 2020 was $75,200.

NOTE 5 – COMMON STOCK TRANSACTIONS

A summary of the Company’s stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 and 2019 is as follows:

During the six months ended October 31, 2019, the Company issued 2,000,000 shares of common stock to four non-employee members of the Company’s Board of Directors (“Board”) pursuant to Director Letter Agreements (“DLAs”) with the Company for services relating to the prior year. The shares vested upon issuance and the Company recorded a non-cash expense of $0 and $0 and for the three and six months ended October 31, 2020, respectively, and $5,408 and $19,212 for the three and six months ended October 31, 2019, respectively.

Effective July 1, 2018, the Company issued 1,200,000 shares of common stock to a consultant. The term of the agreement is for twelve months. The shares vest monthly over a twelve-month period and are subject to the consultant providing services under the agreement. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $0 and $12,816 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares as of October 31, 2020 and 2019, respectively.

During the month of April 2019, two consultants were issued 2,500,000 shares of common stock pursuant to their consulting agreements. The term of the agreements is for twelve months which covered prior and current periods. The shares vest monthly over a twelve-month period and are subject to the consultants providing services under their respective consulting agreements. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $4,701 and $11,910 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares as of October 31, 2020 and 2019.

During the six months ended October 31, 2019, a consultant was issued 500,000 shares of common stock pursuant to his consulting agreement with the Company. The term of the consulting agreement is for twelve months which covered prior and current periods. The shares vest monthly over a twelve-month period and are subject to the consultant providing services under his consulting agreement. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $0 and $3,306 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares as of October 31, 2020 and 2019.

In January 2019, the Company awarded 6,600,000 shares of common stock to executive officers of the Company as part of their compensation agreements for 2019. These shares vest monthly over a twelve-month period and are subject to them continuing service under their compensation agreements. During the three and six months ended October 31, 2020, the Company recorded a non-cash compensation expense in the amount of $0 and $0, respectively, and $104,727 and $209,453 for the three and six months ended October 31, 2019, respectively. There were zero and 1,100,000 unvested shares as of October 31, 2020 and 2019, respectively.

During the six months ended October 31, 2019, four non-employee members of the Board were issued 2,000,000 shares of common stock pursuant to their DLAs with the Company. The shares were fully vested upon issuance. The Company recorded a non-cash expense of $3,205 and $10,561 for the three and six months ended October 31, 2020, respectively, and $15,793 and $27,435 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to these DLAs as of October 31, 2020 and 2019.

During the six months ended October 31, 2019, a consultant was issued 2,000,000 shares of common stock in respect of his services as the Chairman of the Company’s Medical and Scientific Advisory Board over a four-year period with their vesting subject to the consultant providing services to the Company. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $4,701 and $11,851 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to his compensation arrangement as of October 31, 2020 and 2019.

During the six months ended October 31, 2020, four non-employee members of the Board were issued 2,000,000 shares of common stock pursuant to their DLAs in respect of their service during that year. The shares were fully vested upon issuance. The Company recorded a non-cash expense of $9,419 and $16,448 for the three and six months ended October 31, 2020, respectively, and $0 and $0 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to such DLAs as of October 31, 2020.

During the six months ended October 31, 2020, four consultants were issued 1,000,000 shares of common stock pursuant to their consulting agreements with the Company. The terms of the agreements are for twelve months. The shares vest monthly over a twelve-month period and are subject to the consultants providing services under the consultant’s consulting agreements. The Company recorded a non-cash consulting expense in the amount of $5,409 and $9,608 for the three and six months ended October 31, 2020, respectively, and $0 and $0 for the three and six months ended October 31, 2019, respectively. There were 500,000 unvested shares remaining related to these consulting agreements as of October 31, 2020.

In January 2020, the Company awarded 6,600,000 shares of common stock to the executive officers of the Company as part of their compensation agreements. These shares vest monthly over a twelve-month period and are subject to them continuing service under their compensation agreements. During the three and six months ended October 31, 2020, the Company recorded a non-cash compensation expense in the amounts of $67,320 and $134,640, respectively. There were 1,100,000 unvested shares as of October 31, 2020.

During the six months ended October 31, 2020, a consultant was issued 500,000 shares of common stock in respect of his services as the Chairman of the Company’s Medical and Scientific Advisory Board with the vesting subject to the consultant providing services to the Company. The Company recorded a non-cash consulting expense in the amount of $708 and $708 for the three and six months ended October 31, 2020, respectively, and $0 and $0 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to his compensation arrangement as of October 31, 2020 and 2019.

All shares listed above were issued without registration under the Securities Act in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act.

During the six months ended October 31, 2020 and 2019, the Company sold and issued approximately 693 million and 137 million shares of common stock, respectively, at prices of approximately $0.01 per share pursuant to the Company’s S-3. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received net proceeds of approximately $4.7 million and $884,000 from the sale of these shares for the six months ended October 31, 2020 and 2019, respectively.

A summary of the Company’s unvested restricted stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 are as follows:

	Shares			Weighted Average Grant Date Fair Value

Unvested, at April 30, 2020		4,600,000		$	0.06
Granted		3,500,000			0.02
Vested		(6,500,000	)		0.03
Forfeited		–			–

Unvested, at October 31, 2020		1,600,000		$	0.03

NOTE 6 – STOCK OPTIONS AND WARRANTS

Stock Options

As of October 31, 2020, the Company had 69,200,000 outstanding stock options to its directors and executive officers (collectively, “Employee Options”) and consultants (“Non-Employee Options”).

During the six months ended October 31, 2020 and 2019, the Company granted 2,000,000 and 2,000,000 Employee Options, respectively.

The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions:

	Six Months Ended October 31,
	2020			2019
Risk-free interest rate		0.3	%		2.0	%
Expected volatility		92	%		91	%
Expected term (years)		2.5			2.5
Expected dividend yield		0.00	%		0.00	%

The Company’s computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For stock option grants issued during the six months ended October 31, 2020 and 2019, the Company used a calculated volatility for each grant. The Company lacks adequate information about the exercise behavior and therefore has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company’s stock options of five years with the average vesting term of two and one-half years for an average of 2.5 years. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life.

During the six months ended October 31, 2020 and 2019, the Company granted zero and 1,200,000 Non-Employee Options, respectively. During the three months ended October 31, 2020 and 2019, the Company granted zero and 1,200,000 Non-Employee Options, respectively.

A summary of the Company’s stock option activity and related information for the six months ended October 31, 2020 is shown below:

	Options		Weighted Average Exercise Price per Share		Weighted Average Grant Date Fair Value per Share

Outstanding, April 30, 2020		67,200,000	$	0.06	$	0.06
Granted		2,000,000		0.02		0.02
Forfeited		–		–		–
Exercised		–		–		–
Outstanding, October 31, 2020		69,200,000	$	0.06	$	0.06
Exercisable, October 31, 2020		67,700,000	$	0.06	$	–
Vested and expected to vest		69,200,000	$	0.06	$	–

A summary of the activity for unvested stock options during the six months ended October 31, 2020 is as follows:

	Options			Weighted Average Grant Date Fair Value per Share

Unvested, April 30, 2020		6,200,000		$	0.05
Granted		2,000,000			0.02
Vested		(6,700,000	)		–
Forfeited		–			–
Unvested, October 31, 2020		1,500,000		$	0.04

The Company recorded $56,059 and $93,995 of stock-based compensation expense related to the issuance of Employee Options to certain executive officers and directors in exchange for services during the three months ended October 31, 2020 and 2019, respectively, and $128,376 and $210,909 during the six months ended October 31, 2020 and 2019, respectively. At October 31, 2020, there remained $35,410 of unrecognized compensation expense related to unvested Employee Options granted to executive officers and directors, to be recognized as expense over a weighted-average period of the remaining two months in the calendar year. The unvested options vest at 750,000 shares per month and are expected to be fully vested on December 31, 2020.

The Company recorded $0 and $4,414 of stock-based compensation related to the issuance of Non-Employee Options in exchange for services during the three months ended October 31, 2020 and 2019, respectively, and $0 and 13,825 during the six months ended October 31, 2020 and 2019, respectively. There were no unvested Non-Employee Options on October 31, 2020.

The following table summarizes the outstanding stock options by exercise price at October 31, 2020:

Exercise Price		Number of Options Outstanding		Weighted Average Remaining Contractual Life of Outstanding Options (years)		Weighted Average Exercisable Price		Number of Options Exercisable		Weighted Average Exercise Price of Exercisable Options
$	0.063		15,600,000		0.10	$	0.063		15,600,000	$	0.063
$	0.104		10,450,000		0.87	$	0.104		10,450,000	$	0.104
$	0.0685		600,000		0.50	$	0.0685		600,000	$	0.0685
$	0.058		2,450,000		1.24	$	0.058		2,450,000	$	0.058
$	0.0734		1,200,000		0.84	$	0.0734		1,200,000	$	0.0734
$	0.0729		1,800,000		1.69	$	0.0729		1,800,000	$	0.0729
$	0.089		1,200,000		1.71	$	0.089		1,200,000	$	0.089
$	0.0553		500,000		0.97	$	0.0553		500,000	$	0.0553
$	0.0558		9,000,000		1.30	$	0.0558		9,000,000	$	0.0558
$	0.0534		1,200,000		2.85	$	0.0534		1,200,000	$	0.0534
$	0.0539		1,000,000		1.25	$	0.0539		1,000,000	$	0.0539
$	0.0683		500,000		1.33	$	0.0683		500,000	$	0.0683
$	0.0649		500,000		1.47	$	0.0649		500,000	$	0.0649
$	0.0495		9,000,000		2.03	$	0.0495		9,000,000	$	0.0495
$	0.0380		1,200,000		3.90	$	0.0380		1,200,000	$	0.0380
$	0.0404		1,000,000		1.75	$	0.0404		1,000,000	$	0.0404
$	0.0370		500,000		1.83	$	0.0370		500,000	$	0.0370
$	0.0340		500,000		1.97	$	0.0340		500,000	$	0.0340
$	0.0408		9,000,000		2.51	$	0.0408		7,500,000	$	0.0408
$	0.0240		1,000,000		2.25	$	0.0240		1,000,000	$	0.0240
$	0.0247		500,000		2.33	$	0.0247		500,000	$	0.0247
$	0.0105		500,000		2.47	$	0.0105		500,000	$	0.0105
	Total		69,200,000		1.32	$	0.06		67,700,000	$	0.06

The aggregate intrinsic value of outstanding options as of October 31, 2020 was zero. This represents options whose exercise price was less than the closing fair market value of the Company’s common stock on October 31, 2020 of approximately $0.0089 per share.

Warrants

The warrants issued by the Company are equity-classified. The fair value of the warrants was recorded as additional paid-in-capital, and no further adjustments are made.

For stock warrants paid in consideration of services rendered by non-employees, the Company recognizes consulting expense in accordance with the requirements of ASC 505. Common Stock Purchase Warrants issued in conjunction with Block Trade transactions to Aeon Capital, Inc. (‘Aeon”) are accounted for in accordance with ASC 815-40, with the fair value recorded to additional paid-in capital and offsetting amounts recorded as equity issuance costs on the Condensed Consolidated Statement of Stockholders’ Equity.

Effective June 13, 2019, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,338,889 shares of common stock based upon the Block Trade transaction pursuant to the Company’s engagement agreement with Aeon dated February 22, 2018 (“Aeon Engagement Agreement”). The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $9,000. The warrants have a cashless exercise feature.

Effective July 15, 2019, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,944,444 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $12,000. The warrants have a cashless exercise feature.

Effective August 7, 2019, the Company issued two Common Stock Purchase Warrants to Aeon for two Block Trade transactions. The Company issued two warrants to purchase a total of 3,500,000 shares of common stock based on two Block Trades pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate value of these warrants to be approximately $12,000. The warrants have a cashless exercise feature.

Effective July 10, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 4,100,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $29,000. The warrants have a cashless exercise feature.

Effective July 18, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 3,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $18,000. The warrants have a cashless exercise feature.

Effective July 19, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,333,333 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $7,000. The warrants have a cashless exercise feature.

Effective July 27, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 2,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $13,000. The warrants have a cashless exercise feature.

Effective August 3, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 4,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $24,000. The warrants have a cashless exercise feature.

Effective August 6, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 4,100,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $29,000. The warrants have a cashless exercise feature.

Effective August 6, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 5,000,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $18,000. The warrants have a cashless exercise feature.

Effective August 7, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 2,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $13,000. The warrants have a cashless exercise feature.

Effective August 7, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 5,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $19,000. The warrants have a cashless exercise feature.

Effective August 10, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,333,333 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $7,000. The warrants have a cashless exercise feature.

A summary of the Company’s warrant activity and related information for the six months ended October 31, 2020 is shown below:

	Warrants		Weighted Average Exercise Price
Outstanding, April 30, 2020		47,890,155	$	0.05
Issued		34,366,666		0.01
Expired		–		–
Outstanding, October 31, 2020		82,256,821		0.03
Exercisable, October 31, 2020		82,256,821	$	0.03

The following table summarizes additional information concerning warrants outstanding and exercisable at October 31, 2020:

Exercise Prices	Number of Warrant Shares Exercisable at April 30, 2020		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price

$0.12		17,000,000		0.19
$0.065		769,231		1.13
$0.0575		869,565		1.42
$0.03		2,500,000		2.07
$0.026		1,923,077		2.66
$0.025		2,000,000		1.73
$0.018		1,388,889		2.58
$0.011		2,272,727		3.00
$0.01		13,200,000		4.42
$0.015		833,333		4.47
$0.009		3,333,333		3.67
$0.0075		15.666.666		4.74
$0.005		20,500,000		4.13
		82,256,821		3.28	$	0.03

NOTE 7 – LEGAL PROCEEDINGS

The Company is not currently a party to any pending legal proceedings, material or otherwise. There are no legal proceedings to which any property of the Company is subject.

NOTE 8 – RELATED PARTY TRANSACTIONS

The Company had the following related party transactions during the three and six months ended October 31, 2020 and 2019.

The Company owns 14.5% of the equity in SG Austria and is reported on the cost method of accounting. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand Company Ltd. The Company purchased products and services from these subsidiaries in the approximate amounts of $10,000 and $74,000 in the three and six months ended October 31, 2020, respectively, and $0 and $2,400 for the three and six months ended October 31, 2019, respectively.

In April 2014, the Company entered the Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Walter H. Günzburg (“Prof. Günzburg) and Dr. Brian Salmons (“Dr. Salmons”), both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes (Prof. Gunzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months, automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. The agreement has been automatically renewed annually. The amounts incurred for the three and six months ended October 31, 2020 were approximately $21,000 and $44,000, respectively, and $2,000 and $15,000 for the three and six months ended October 31, 2019, respectively. In addition, during the six months ended October 31, 2020 the Company issued 250,000 shares of common stock to Dr. Salmons to be a member of the Company’s Medical and Scientific Advisory Board. The Company recorded a noncash consulting expense of approximately $2,300 relating to this share issuance for the six months ended October 31, 2020.

During the year ended April 30, 2020, the Company issued one share of Series A Preferred Stock to the Chief Executive Officer of the Company for $1 pursuant to a Subscription Agreement. The Series A Preferred Stock is described in detail in Note 12 – Preferred Stock. The Board exercised its right to have the Company redeem the one share of Series A Preferred Stock. It is no longer issued and outstanding.

NOTE 9 – COMMITMENTS AND CONTINGENCIES

The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical product if regulatory approval for marketing of the product candidate is obtained.

Office Lease

Effective September 1, 2017, the Company entered into an office lease at 23046 Avenida de la Carlota, Suite 600, Laguna Hills, California (“Leased Premises”). The term of the lease is for 24 months and expired on August 31, 2019. In May 2019, the Company entered into an additional one-year lease for the Leased Premises, commencing upon the expiration of the term of the prior lease. The term of the lease expired on August 31, 2020.

On May 28, 2020, the Company entered into an additional six-month lease of the Leased Premises, commencing on September 1, 2020. The term of the new lease expires on February 28, 2021.

Rent expenses for these offices for the three months ended October 31, 2020 and 2019 were $5,384 and $7,999, respectively, and for the six months ended October 31, 2020 and 2019 were $12,536 and $16,660, respectively.

The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of October 31, 2020.

	Amount
2021	$	5,144
	$	5,144

Compensation Agreements

The Company entered into executive compensation agreements with its three executive officers in March 2015, each of which was amended in December 2015 and March 2017. Each agreement has a term of two years with automatic annual extensions thereafter unless the Company or the executive officer provides written notification of termination at least ninety days prior to the end of the term or subsequent extensions. The Company also entered a compensation agreement with a Board member in April 2015 which continued in effect until amended in May 2017.

In May 2017, the Company amended the compensation agreement with the Board members and the terms continue in effect until a member is no longer on the Board.

The Company has four independent directors. Each director receives the same compensation: (i) $12,500 in cash for each calendar quarter of service on the Board; (ii) 500,000 fully-paid, non-assessable shares of the Company’s restricted common stock (“Shares”) annually; and (iii) a five-year option to purchase 500,000 Shares annually at an exercise price equal to the fair market value of the Shares on the date of grant. The Shares and the option Shares fully vest on the date of the grants.

NOTE 10 - INCOME TAXES

The Company had no income tax expense for the six months ended October 31, 2020 and 2019, respectively. During the six months ended October 31, 2020 and 2019, the Company had a net operating loss (“NOL”) for each period which generated deferred tax assets for NOL carryforwards. The Company provided valuation allowances against the net deferred tax assets including the deferred tax assets for NOL carryforwards. Valuation allowances provided for the net deferred tax asset increased by approximately $355,000 and $449,000 for the six months ended October 31, 2020 and 2019, respectively.

There was no material difference between the effective tax rate and the projected blended statutory tax rate for the six months ended October 31, 2020 and 2019.

Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. Based on the assessment of all available evidence including, but not limited to, the Company’s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulations and healthcare reform initiatives and other risks normally associated with biotechnology companies, the Company has concluded that is more-likely-than-not that these operating loss carryforwards will not be realized. Accordingly, 100% of the deferred tax valuation allowance has been recorded against these assets at October 31, 2020.

The Company’s policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of the six months ended October 31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions.

See Note 10 of Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended April 30, 2020 for additional information regarding income taxes.

NOTE 11 – EARNINGS PER SHARE

Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares and potentially dilutive shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would be outstanding if the potentially dilutive securities had been issued. Potential shares of common stock outstanding principally include stock options and warrants. During the six months ended October 31, 2020 and 2019, the Company incurred losses. Accordingly, the effect of any common stock equivalent would be anti-dilutive during those periods and are not included in the calculation of diluted weighted average number of shares outstanding.

The table below sets forth the basic loss per share calculations:

	Three Months Ended October 31,
	2020			2019
Net loss	$	(950,192	)	$	(1,067,122	)
Basic weighted average number of shares outstanding		2,309,218,013			1,325,086,933
Diluted weighted average number of shares outstanding		2,309,218,013			1,325,086,933
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)

	Six Months Ended October 31,
	2020			2019
Net loss	$	(1,834,136	)	$	(2,201,197	)
Basic weighted average number of shares outstanding		1,993,895,090			1,267,696,383
Diluted weighted average number of shares outstanding		1,993,895,090			1,267,696,383
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)

The table below sets forth these potentially dilutive securities:

	Six Months Ended October 31,
	2020		2019
Excluded options		69,200,000		85,650,000
Excluded warrants		82,256,821		48,056,822
Total excluded options and warrants		151,456,821		133,706,822

NOTE 12 – PREFERRED STOCK

The Company has authorized 10,000,000 shares of preferred stock, with a par value of $0.0001, of which one share has been designated as "Series A Preferred Stock". The one share of Series A Preferred Stock was issued on October 30, 2019 and repurchased by the Company on December 3, 2019. As of October 31, 2020, there are no shares of preferred stock issued and outstanding.

The description of the Series A Preferred Stock below is qualified in its entirety by reference to the Company’s Articles of Incorporation, as amended.

The Series A Preferred Stock has the following features:

	•	There is one share of preferred stock designated as Series A Preferred Stock;

	•	The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders of the Company having a right to vote on any matter plus one. The Certificate of Designations that designated the terms of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock;

	•	The Company may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series A Preferred Stock; and

	•	The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation in any distributions to shareholders.

NOTE 13 – SUBSEQUENT EVENTS

On November 19, 2020, the Company sent Hai Kang a letter terminating the Hai Kang License Agreement. The Company did so out of concerns over the failure to timely obtain an FDA Emergency Use Authorization for the Kits and the efficacy of the Kits. The Company is no longer pursuing this endeavor.

On December 2, 2020, the Company entered into a six-month office lease extension commencing on March 1, 2021. The lease extension is for the office where the Company is currently located in Laguna Hills, California. The term of the new lease expires on August 31. 2021 and requires monthly lease payments of approximately $1,300.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Report includes “forward-looking statements” within the meaning of the federal securities laws. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Report, including any projections of earnings, revenue or other financial items, any statements regarding the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, any statements regarding expected benefits from any transactions and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by use of terminology such as “may,” “will,” “should,” “believes,” “intends,” “expects,” “plans,” “anticipates,” “estimates,” “goal,” “aim,” “potential” or “continue,” or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future, including risks relating to the continuing outbreak of COVID-19. Although we believe that the expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Thus, investors should refer to and carefully review information in future documents we file with the Commission. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risk and uncertainties, including, but not limited to, the risk factors set forth in “Part I, Item 1A – Risk Factors” set forth in our Form 10-K for period ended April 30, 2020 and for the reasons described elsewhere in this Report. Among others, these include our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; whether the FDA lifts its clinical hold after we have submitted our responses to the FDA concerns related to our IND submission so that we can commence our planned clinical trial involving LAPC; the success and timing of our preclinical studies and clinical trials; the potential that results of preclinical studies and clinical trials may indicate that any of our technologies and product candidates are unsafe or ineffective; our dependence on third parties in the conduct of our preclinical studies and clinical trials; the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates; the material adverse impact that COVID-19 may have on our business, including our efforts to have the clinical hold lifted and our planned clinical trial involving LAPC, which could materially affect our operations as well as the business or operations of third parties with whom we conduct business; and whether the FDA will approve our product candidates after our clinical trials are completed, assuming the FDA allows our clinical trial to proceed after review of our clinical hold submission. All forward- looking statements and reasons why results may differ included in this Report are made as of the date hereof, and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Report, the “Company,” “we,” “us” and “our” refer to PharmaCyte Biotech, Inc., a Nevada corporation, and, where appropriate, its subsidiaries.

Product Candidates

We are a biotechnology company focused on developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box^®.” The Cell-in-a-Box^®technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC and Type 1 and insulin dependent Type 2 diabetes will be developed.

We are developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that we believe are capable of converting a cancer prodrug into its cancer-killing form, encapsulating those cells using the Cell-in-a-Box^®technology and placing those capsules in the body as close as possible to the tumor. In this way, we believe that when the cancer prodrug is administered to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient’s tumor may be optimized.

We are also examining ways to exploit the benefits of the Cell-in-a-Box^® technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant; these constituents are of the class of compounds known as “cannabinoids”. Until the FDA allows us to commence the clinical trial involving LAPC described in our recently submitted IND for which the FDA has placed a clinical hold, we will not spend any further resources developing this program.

In addition, we are developing a therapy to delay the production and accumulation of malignant ascites fluid that results from many types of abdominal cancerous tumors. Malignant ascites fluid is secreted by abdominal cancerous tumors into the abdomen after the tumors have reached a certain stage of growth. This fluid contains cancer cells that can seed and form new tumors throughout the abdomen. This fluid accumulates in the abdominal cavity, causing swelling of the abdomen, severe breathing difficulties and extreme pain. We are using our therapy for pancreatic cancer to determine if it can prevent or delay the production and accumulation of malignant ascites fluid. As with our Cannabis program, until the FDA allows us to commence the clinical trial involving LAPC described in our recently submitted IND for which the FDA has placed a clinical hold, we will not spend any further resources developing this program.

We are also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Our diabetes therapy consists of encapsulated genetically modified human liver cells and insulin-producing stem cells. The encapsulation for each type of cell will be done using the Cell-in-a-Box^®technology. Implanting these cells in the body is designed to function as a bio-artificial pancreas for purposes of insulin production. As with the two previous programs, we are not spending any further resources developing this program until the FDA allows us to commence the clinical trial involving LAPC described in our recently submitted IND for which the FDA has placed a clinical hold. However, related work at UTS on the Melligen cells continues. Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body.

Finally, we have licensed from Hai Kang the right to certain technology owned or controlled by Hai Kang related to COVID-19 diagnostic Kits. Our license is both for the sale of Kits as well as for the use of the technology underlying the Kits.

On November 19, 2020, we sent Hai Kang a letter terminating the Hai Kang License Agreement. We did so out of concerns over the failure to timely obtain an FDA Emergency Use Authorization for the Kits and the efficacy of the Kits.

Clinical Hold

On September 1, 2020, we submitted an IND to the FDA for a planned Phase 2b clinical trial in LAPC. Shortly thereafter, we received Information Requests from the FDA related to the IND. We timely responded to all information requests

On October 1, 2020, we received notice that the FDA had placed the IND on clinical hold.

On October 30, 2020, the FDA sent a letter to us setting forth the reasons for the clinical hold and specific guidance on what we must do to have the clinical hold lifted.

In order to address the clinical hold, the FDA has requested that we:

Provide additional sequencing data and genetic stability studies;

Conduct a stability study on the final formulated drug product as well as the cells from the Master Cell Bank;

Evaluate the compatibility of the delivery devices (i.e., the prefilled syringe and microcatheter) with the drug product;

Provide additional detailed description of the manufacturing process;

Provide additional product release specifications for the encapsulated cells;

Demonstrate comparability between the 1st and 2nd generation products and ensure adequate and consistent product performance and safety between the two generations;

Conduct a biocompatibility assessment using the final finished capsules after the entire drug product manufacturing process (but without cells);

Address insufficiencies in Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File;

Conduct an additional nonclinical study to assess the safety, activity and distribution of the drug product;

Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data; and

Provide data from a new pig study.

The FDA also requested that we address several issues not related to the clinical hold in an amendment to the IND, including:

Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency;

Perform qualification studies for the drug substance filling step to ensure that the product remains sterile and stable during the filling process;

Submit an updated batch analysis for the drug product for the specific lot that will be used for manufacturing all future drug product;

Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays;

Provide a few examples of common microcatheters that fit the specifications in the Angiography Procedure Manual;

Clarify the language in the Pharmacy Manual regarding proper use of the syringe fill with the drug product; and

Provide a discussion with data for the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in the Company’s study population.

There has been no further communication with the FDA regarding the clinical hold.

We have assembled a scientific team to address the FDA requests related to the clinical hold. That team is working to complete the items requested by the FDA. We have not yet determined the estimated cost and the time necessary to complete these items. The cost and time associated with completing these items will likely be significant.

COVID-19 Potential Impact on the Financial Condition and Results of Operations

The development of our product candidates could be disrupted and materially adversely affected in the future by a pandemic like the continuing outbreak of COVID-19. For example, as a result of measures imposed by the governments in states affected by COVID-19, businesses and schools have been suspended due to quarantines or stay at home orders intended to contain the pandemic. COVID-19 continues to spread globally and, as of October 31, 2020, has spread to over 151 countries, including the U.S. While COVID-19 is thought to be in its middle stages, international stock markets continue to reflect the uncertainty associated with the slow-down in the world economies and the reduced levels of international travel experienced since the beginning of January 2020. As of the date of this Report, COVID-19 has had an impact upon our operations, although we believe that impact is not material.

We are still assessing our business plans and the impact COVID-19 may have on our ability to advance the development of our product candidates or to raise financing to support the development of our product candidates, but no assurances can be given that this assessment will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in the business sector generally or in our sector in particular. The spread of COVID-19 may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators’ and potential strategic partners’ ability to work to have the clinical hold lifted, including the preclinical work needed to lift the clinical hold and our other operations. COVID-19 could materially affect our operations, as well as the business or operations of third parties with whom we conduct business. Our business could be adversely affected by the effects of other future health pandemics in regions where we or third parties on which we rely have significant business operations. See the risk factors set forth in “Part I, Item 1A – Risk Factors” set forth in our Form 10-K for period ended April 30, 2020 and for the reasons described elsewhere in this Report.

Performance Indicators

Non-financial performance indicators used by management to manage and assess how the business is progressing will include, but are not limited to, the ability to: (i) acquire appropriate funding for all aspects of our operations; (ii) acquire and complete necessary contracts; (iii) complete activities for producing genetically modified human cells and having them encapsulated for our preclinical studies and the planned clinical trial in LAPC; (iv) have regulatory work completed to enable studies and trials to be submitted to regulatory agencies; (v) complete all required tests and studies on the cells and capsules we plan to use in our clinical trial in patients with LAPC; and (vi) ensure completion of the production of encapsulated cells according to current Good Manufacturing Practices regulations to use in our planned clinical trial involving LAPC.

There are numerous items required to be completed successfully to ensure our final product candidate is ready for use in our planned clinical trial involving LAPC. The effects of material transactions with related parties, and certain other parties to the extent necessary for such an undertaking, may have substantial effects on both the timeliness and success of our current and prospective financial position and operating results. Nonetheless, we are actively working to ensure strong ties and interactions to minimize the inherent risks regarding success. We do not believe there are factors which will cause materially different amounts to be reported than those presented in this Report. We aim to assess this regularly to provide accurate information to our shareholders.

Results of Operations

Three and six months ended October 31, 2020 compared to three and six months ended October 31, 2019

Revenue

We had no revenues for the three and six months ended October 31, 2020 and 2019.

Operating Expenses and Loss from Operations

The following table summarizes our operating expenses and loss from operations for the three and six months ended October 31, 2020 and 2019, respectively:

Three Months Ended October 31,				Six Months Ended October 31,
2020		2019		2020		2019
$	949,515	$	1,067,122	$	1,831,191	$	2,201,197

The total operating expenses for the three-month period ended October 31, 2020 decreased by $117,607 from the three months ended October 31, 2019. The decrease is attributable to a decrease in general and administrative (“G&A”) expenses of $316,718, a decrease in director fees of $13,537, a decrease in legal and professional expense of $27,042 net of an increase in compensation expense of $106,316 and an increase in R&D expense of $133,374. The decrease in G&A expenses were mainly attributable to reductions in consulting fees and travel expenses.

The total operating expenses for the six-month period ended October 31, 2020 decreased by $370,006 from the six months ended October 31, 2019. The decrease is attributable to a decrease in general and administrative (“G&A”) expenses of $621,118, a decrease in director fees of $17,155, a decrease in compensation expense of $67,908, net of an increase in legal and professional expense of $4,557, and an increase in R&D expense of $331,618. The decrease in G&A expenses were mainly attributable to reductions in consulting fees and travel expenses.

Other expense

The following table sets forth our other expense for the three and six months ended October 31, 2020 and 2019:

Three Months Ended October 31,				Six Months Ended October 31,
2020		2019		2020		2019
$	677	$	–	$	2,945	$	–

Total other expense for the three months ended October 31, 2020 increased by the amount of $677 from the three months ended October 31, 2019. The increase is attributable to the increase of interest expense in the amount of $677.

Total other expense for the six months ended October 31, 2020 increased by the amount of $2,945 from the six months ended October 31, 2019. The increase is attributable to the increase of interest expense in the amount of $1,757, an increase in income taxes of $800 and an increase in foreign exchange losses of $388.

Discussion of Operating, Investing and Financing Activities

The following table presents a summary of our sources and uses of cash for the six months ended October 31, 2020 and 2019, respectively:

	Six Months Ended
	October 31, 2020			October 31, 2019
Net cash used in operating activities:	$	(1,801,453	)	$	(1,346,765	)
Net cash provided by (used in) investing activities:		–			–
Net cash provided by financing activities:		4,624,171			883,501
Effect of currency rate exchange		(175	)		(6,928	)
Net increase (decrease) in cash	$	2,822,543		$	(470,192	)

Operating Activities:

The net cash used in operating activities for the six months ended October 31, 2020 is a result of our net losses, decreases in accounts payable, accrued expenses and a decrease in prepaid expenses and an increase in securities issued for services and compensation. The cash used in operating activities for the six months ended October 31, 2019 is a result of our net losses, offset by an increase in stock issued, an increase in prepaid expenses and increases in accounts payable and accrued expenses. See Condensed Consolidated Statements of Cash Flows on page 7.

Investing Activities:

There were no investing activities in the six months ended October 31, 2020 and 2019.

Financing Activities:

The cash provided from financing activities is mainly attributable to the proceeds from the sale of our common stock net of the use of funds for payment of director and officer insurance financing.

Liquidity and Capital Resources

As of October 31, 2020, our cash totaled approximately $3,717,000, compared to approximately $45,000 at October 31, 2019. Working capital was approximately $3,169,000 at October 31, 2020 and approximately a negative $595,000 at October 31, 2019. The increase in cash is attributable to a higher beginning cash balance, an increase in proceeds from the sale of our common stock offset by a decrease in our operating expenses.

During the six months ended October 31, 2020, funding was provided by investors to maintain and expand our operations and R&D. Sales of our common stock were consummated using the S-3. During the six months ended October 31, 2019, we continued to acquire funds through our S-3 pursuant to Block Trades transactions in a program which is structured to provide up to $25 million dollars to us less certain commissions pursuant to the S-3.

As of August 13, 2020, we no longer met the eligibility requirements to use the S-3.

In Note 2 – Going Concern to our Condensed Consolidated Financial Statements set forth in this Report, we note that certain conditions raise substantial doubt about our ability to continue as a going concern.

Off-Balance Sheet Arrangements

Except as described below, we have no off-balance sheet arrangements that could have a material current effect or that are reasonably likely to have a material adverse effect on our financial condition, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Service Agreements

We entered into several service agreements with independent and related parties pursuant to which services will be provided over the next twenty-four months related to our IND and clinical trial involving LAPC. The services include regulatory affairs strategy, advice and follow up work on the IND and services related to having the clinical hold lifted. They also cover a 24-month stability study, which includes the container closure integrity testing, of the clinical trial product syringes. The total cost is estimated to be approximately $100,000, of which the related party portion will be approximately $80,000. These amounts do not take into account the cost associated with the work and preclinical studies required to lift the clinical hold.

New Accounting Pronouncements

For a discussion of all recently adopted and recently issued but not yet adopted accounting pronouncements, see Note 2 “Summary of Significant Accounting Policies” of the Notes to our Condensed Consolidated Financial Statements contained in this Report.

Available Information

Our website is located at www.PharmaCyte.com, In addition, all our filings submitted to the Commission, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all our other reports and statements filed with the Commission are available on the Commission’s web site at www.sec.gov. Such filings are also available for download free of charge on our website. The contents of the website are not, and are not intended to be, incorporated by reference into this Report or any other report or document filed with the Commission or furnished by us, and any reference to the websites are intended to be inactive textual references only.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The information called for by Item 3 is not required for a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer, President and General Counsel, as our principal executive officer (“Chief Executive Officer”), and our Chief Financial Officer, as our principal financial officer (“Chief Financial Officer”), evaluated the effectiveness of our “disclosure controls and procedures,” as such term is defined in Rules 13a - 15(e) and 15d - 15(e) promulgated under the Securities Exchange Act of 1934, as amended, (“Exchange Act”). Disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or submit to the Commission pursuant to the Exchange Act are recorded, processed, summarized and reported within the period specified by the Commission’s rules and forms and are accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosures. Based upon this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of October 31, 2020, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Also, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Management’s Report on Internal Controls over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal controls over financial reporting as that term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.

Under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, management conducted an evaluation of the effectiveness of our internal controls over financial reporting as of October 31, 2020 based on the criteria outlined in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and identified the following material weaknesses in internal controls over financial reporting:

	·	Insufficient procedures and control documentation to implement control procedures including lack of timely contract preparation and review. We have developed procedures to provide ample review time of financial information, including contract preparation and review by qualified personnel as well as management. We have implemented these procedures, determined they are still insufficient and will continue to review these procedures to determine ways to further improve them.

	·	Insufficient segregation of duties of the Chief Financial Officer. We have delegated some of the duties of our Chief Financial Officer to other personnel within the Company and have added review and approval processes performed by the Chief Executive Officer. However, we have determined that we still have insufficient segregation of the duties of our Chief Financial Officer and will continue to review these procedures to determine ways to further improve them given our limited staff.

	·	Insufficient information technology controls and documentation. We currently use accounting software which we have determined is inadequate to provide the level of controls required by COSO. We are in the process of initiating a review process to fully evaluate the deficiencies in our technology controls and documentation. Based upon the results of this review process, we intend to implement the required remediation measures when it is reasonable to do so.

Because of these material weaknesses, our Chief Executive Officer and our Chief Financial Officer concluded that, as of October 31, 2020, our internal controls over financial reporting were not effective based on the COSO criteria.

We are in the process of investigating new procedures and controls for the balance of fiscal year 2021. At the appropriate time we plan to make changes to our procedures and controls that we believe are reasonable and reasonably likely to strengthen and materially affect our internal controls over financial reporting.

Prior to the remediation of these material weaknesses, there remains risk that the processes and procedures on which we currently rely will fail to be sufficiently effective, which could result in material misstatement of our financial position or results of operations and require a restatement. Because of the inherent limitations in all control systems, no evaluation of controls - even where we conclude the controls are operating effectively - can provide absolute assurance that all control issues, including instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of a person, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events; accordingly, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, our control systems, as we develop them, may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected and could be material to our financial statements.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal controls over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

The Certifications of our Principal Executive Officer and Principal Financial Officer required in accordance with Rule 13a-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002 (“Certifications”) are attached to this Report. The disclosures set forth in this Item 4 contain information concerning: (i) the evaluation of our disclosure controls and procedures, and changes in internal control over financial reporting, referred to in paragraph 4 of the Certifications; and (ii) material weaknesses in the design or operation of our internal control over financial reporting, referred to in paragraph 5 of the Certifications. The Certifications should be read in conjunction with this Item 4 for a more complete understanding of the matters covered by the Certifications.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any material pending legal proceedings. There are no material legal proceedings to which any property of ours is subject.

Item 1A. Risk Factors.

In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Form 10-K filed with the Commission on August 13, 2020. The information set forth therein and in this Report could materially affect our business, financial position and results of operations. There are no material changes from the risk factors set forth the 10-K, except as follows:

As a result of the clinical hold that has been placed on our IND by the FDA, it may take considerable time and expense to respond to the FDA and no assurance can be given that the FDA will remove the clinical hold in which case our business and prospects may suffer material adverse consequences.

On October 1, 2020, we received notice that the FDA had placed our IND for a planned Phase 2b clinical trial in LAPC on clinical hold. As part of the clinical hold process, the FDA has asked for additional information, tasks to be performed by us and new preclinical studies. It may take a considerable period of time, the length of which is unknown at this time, for us to conduct such tasks and preclinical studies and to prepare such requested information. In addition, the significant expense of such work is likely to require us to raise additional capital. It is possible that the service providers that we will utilize for such work may have considerable backlogs and/or are suffering from slowdowns as a result of COVID-19 and may not be able to perform such work for an extended period of time. Even if we are able to fully respond to the FDA’s request, they may subsequently make additional requests that we would need to fulfill prior to the lifting of the clinical hold and we may never be able to begin clinical trials, obtain regulatory approval or obtain commercialization for our product candidates. An inability to conduct clinical trials as a result of the clinical hold or otherwise, would likely force us to terminate our clinical development plans. It is possible that we will be unable to fully respond to the FDA in a satisfactory manner, and as a result the clinical hold may never be lifted. If the clinical hold is not lifted or if the lifting takes an extended period of time, our business and prospects may suffer material adverse consequences.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the six months ended October 31, 2020, we issued an aggregate of 500,000 unregistered shares of common stock to one of our directors as disclosed in this Report. The non-cash expense for this share issuance totaled $5,250.

During the six months ended October 31, 2020, we issued an aggregate of 500,000 stock options to one of our directors pursuant to his DLA. The non-cash expense for this stock option totaled $2,943.

During the six months ended October 31, 2020, we issued an aggregate of 500,000 unregistered shares of common stock to an independent contractor pursuant to his professional services agreements. The non-cash expense for these share issuances totaled $8,500.

During the six months ended October 31, 2020, we issued four Common Stock Purchase Warrants to Aeon for Block Trades transactions. The warrants provide Aeon the right to purchase 22,933,333 shares of common stock based upon these Block Trades pursuant to the Aeon Engagement Agreement. We classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, we determined the aggregate value of these warrants to be approximately $110,000. The warrants have a cashless exercise feature.

All such securities were issued without registration under the Securities Act in reliance upon the exemption afforded by Section 4(a)(2) of that Act based on the limited number of investors, the sophistication of the individuals involved and the use of restrictive legends on the securities issued to prevent a public distribution of the relevant securities. No underwriters were involved in any of these issuances.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosure.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit No.

Description

Location

10.1†	Amendment No. 3, dated as of October 14, 2020, to Executive Compensation Agreement between Gerald W. Crabtree and the Company	Incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 16, 2020.

31.1	Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith

31.2	Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith

32.1	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.	Filed herewith

32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.	Filed herewith

101.	Interactive Data Files for the Company’s Form 10-Q for the period ended October 31, 2020	Submitted herewith.

† Indicates a management contract or any compensatory plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

PharmaCyte Biotech, Inc.

December 11, 2020	By: /s/ Kenneth L. Waggoner
	Kenneth L. Waggoner
	Chief Executive Officer
	(Duly Authorized Officer and Principal Executive Officer)


December 11, 2020	By: /s/ Carlos A. Trujillo
	Carlos A. Trujillo
	Chief Financial Officer
	(Duly Authorized Officer and Principal Financial and Principal Accounting Officer)

EX-31.1 2 pharmacyte_ex3101.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULES 13A-14(A) AND 15D-15(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kenneth L. Waggoner, certify that:

1. I have reviewed the Quarterly Report on Form 10-Q of PharmaCyte Biotech, Inc. (“Report”) and its subsidiaries for the period ended October 31, 2020;

2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

(d) Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 11, 2020

By:

/s/ Kenneth L. Waggoner

Name: Kenneth L. Waggoner

Title: Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 pharmacyte_ex3102.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13A-14(A) AND 15D-15(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Carlos A. Trujillo, certify that:

1. I have reviewed the Quarterly Report on Form 10-Q of PharmaCyte Biotech, Inc. (“Report”) and its subsidiaries for the period ended October 31, 2020;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 11, 2020

By:

/s/ Carlos A. Trujillo

Name: Carlos A. Trujillo

Title: Chief Financial Officer

(Principal Financial and Principal Accounting Officer)

EX-32.1 4 pharmacyte_ex3201.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of PharmaCyte Biotech, Inc. and its subsidiaries (“Company”) on Form 10-Q for the period ended October 31, 2020 as filed with the United States Securities and Exchange Commission (“Commission”) on the date hereof (“Report”), the undersigned, Kenneth L. Waggoner, the Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented.

Dated: December 11, 2020	By:	/s/ Kenneth L. Waggoner
		Name: Kenneth L. Waggoner
		Title: Chief Executive Officer (Principal Executive Officer)

This exhibit shall not be deemed “filed” with the Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing; however, it is instead furnished as provided by applicable rules of the Commission.

EX-32.2 5 pharmacyte_ex3202.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of PharmaCyte Biotech, Inc. and its subsidiaries (“Company”) on Form 10-Q for the period ended October 31, 2020 as filed with the United States Securities and Exchange Commission (“Commission”) on the date hereof (“Report”), the undersigned, Carlos A. Trujillo, the Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented.

Dated: December 11, 2020

By:

/s/ Carlos A. Trujillo

Name: Carlos A. Trujillo

Title: Chief Financial Officer

(Principal Financial and Principal Accounting Officer)

This exhibit shall not be deemed with the Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing ; however, it is instead furnished as provided by applicable rules of the Commission.

EX-101.INS 6 pmcb-20201031.xml XBRL INSTANCE FILE 0001157075 2020-04-30 0001157075 2020-10-31 0001157075 2019-05-01 2019-10-31 0001157075 2020-05-01 2020-10-31 0001157075 pmcb:EmployeeOptionsMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember 2020-04-30 0001157075 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001157075 us-gaap:RetainedEarningsMember 2020-04-30 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-30 0001157075 us-gaap:CommonStockMember 2020-10-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001157075 us-gaap:RetainedEarningsMember 2020-10-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-31 0001157075 us-gaap:CommonStockMember 2019-04-30 0001157075 us-gaap:CommonStockMember 2019-10-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001157075 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001157075 us-gaap:RetainedEarningsMember 2019-04-30 0001157075 us-gaap:RetainedEarningsMember 2019-10-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-30 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001157075 2019-04-30 0001157075 2019-10-31 0001157075 2020-08-01 2020-10-31 0001157075 2019-08-01 2019-10-31 0001157075 2020-12-11 0001157075 pmcb:PreferredStockSeriesAMember 2020-05-01 2020-07-31 0001157075 pmcb:PreferredStockSeriesAMember 2020-08-01 2020-10-31 0001157075 pmcb:PreferredStockSeriesAMember 2019-05-01 2019-07-31 0001157075 pmcb:PreferredStockSeriesAMember 2019-08-01 2019-10-31 0001157075 pmcb:PreferredStockSeriesAMember 2020-04-30 0001157075 pmcb:PreferredStockSeriesAMember 2020-07-31 0001157075 pmcb:PreferredStockSeriesAMember 2020-10-31 0001157075 pmcb:PreferredStockSeriesAMember 2019-04-30 0001157075 pmcb:PreferredStockSeriesAMember 2019-07-31 0001157075 pmcb:PreferredStockSeriesAMember 2019-10-31 0001157075 us-gaap:CommonStockMember 2020-05-01 2020-07-31 0001157075 us-gaap:CommonStockMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember 2019-05-01 2019-07-31 0001157075 us-gaap:CommonStockMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember 2020-07-31 0001157075 us-gaap:CommonStockMember 2019-07-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2020-05-01 2020-07-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2020-10-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2019-05-01 2019-07-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2019-08-01 2019-10-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001157075 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001157075 us-gaap:RetainedEarningsMember 2020-05-01 2020-07-31 0001157075 us-gaap:RetainedEarningsMember 2020-08-01 2020-10-31 0001157075 us-gaap:RetainedEarningsMember 2019-05-01 2019-07-31 0001157075 us-gaap:RetainedEarningsMember 2019-08-01 2019-10-31 0001157075 us-gaap:RetainedEarningsMember 2020-07-31 0001157075 us-gaap:RetainedEarningsMember 2019-07-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-05-01 2020-07-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-01 2020-10-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-01 2019-07-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-08-01 2019-10-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-31 0001157075 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001157075 2020-05-01 2020-07-31 0001157075 2019-05-01 2019-07-31 0001157075 2020-07-31 0001157075 2019-07-31 0001157075 pmcb:SGAustriaMember 2020-10-31 0001157075 pmcb:CellInABoxMember 2020-10-31 0001157075 pmcb:DiabetesLicenseMember 2020-10-31 0001157075 pmcb:BlockTradeTransactionsMember 2020-05-01 2020-10-31 0001157075 pmcb:DAndOInsuranceMember 2020-05-01 2020-10-31 0001157075 pmcb:DAndOInsuranceMember 2020-10-31 0001157075 us-gaap:RestrictedStockMember 2020-05-01 2020-10-31 0001157075 us-gaap:RestrictedStockMember 2020-04-30 0001157075 us-gaap:RestrictedStockMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourDirectorMember pmcb:DirectorLetterAgreementMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourDirectorMember pmcb:DirectorLetterAgreementMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourDirectorMember pmcb:DirectorLetterAgreementMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourDirectorMember pmcb:DirectorLetterAgreementMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2018-05-01 2018-07-01 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:ConsultingAgreementMember 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2018-05-01 2019-04-30 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:TwoConsultantsMember pmcb:ConsultingAgreementsMember 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultant2Member pmcb:ConsultingAgreementMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultant2Member pmcb:ConsultingAgreementMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultant2Member pmcb:ConsultingAgreementMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultant2Member pmcb:ConsultingAgreementMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultant2Member pmcb:ConsultingAgreementMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultant2Member pmcb:ConsultingAgreementMember 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2019Member 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2019Member 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2019Member 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2019Member 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2019Member 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2019Member 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeesMember pmcb:DirectorLetterAgreementMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeesMember pmcb:DirectorLetterAgreementMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeesMember pmcb:DirectorLetterAgreementMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeesMember pmcb:DirectorLetterAgreementMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeesMember pmcb:DirectorLetterAgreementMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeesMember pmcb:DirectorLetterAgreementMember 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:MedicalAndScientificAdvisoryBoardMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:MedicalAndScientificAdvisoryBoardMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:MedicalAndScientificAdvisoryBoardMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:MedicalAndScientificAdvisoryBoardMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:MedicalAndScientificAdvisoryBoardMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantMember pmcb:MedicalAndScientificAdvisoryBoardMember 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeeMember pmcb:DirectorLetterAgreementMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeeMember pmcb:DirectorLetterAgreementMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeeMember pmcb:DirectorLetterAgreementMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeeMember pmcb:DirectorLetterAgreementMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourNonemployeeMember pmcb:DirectorLetterAgreementMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourConsultantsMember pmcb:ConsultingAgreementsMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourConsultantsMember pmcb:ConsultingAgreementsMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourConsultantsMember pmcb:ConsultingAgreementsMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourConsultantsMember pmcb:ConsultingAgreementsMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:FourConsultantsMember pmcb:ConsultingAgreementsMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2020Member 2019-05-01 2020-01-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2020Member 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2020Member 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:OfficersMember pmcb:CompensationAgrmt2020Member 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantsMember pmcb:MedicalAndScientificAdvisoryBoardMember 2020-08-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantsMember pmcb:MedicalAndScientificAdvisoryBoardMember 2020-05-01 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantsMember pmcb:MedicalAndScientificAdvisoryBoardMember 2019-08-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantsMember pmcb:MedicalAndScientificAdvisoryBoardMember 2019-05-01 2019-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantsMember pmcb:MedicalAndScientificAdvisoryBoardMember 2020-10-31 0001157075 us-gaap:CommonStockMember pmcb:AConsultantsMember pmcb:MedicalAndScientificAdvisoryBoardMember 2019-10-31 0001157075 pmcb:ShelfOfferingMember 2020-05-01 2020-10-31 0001157075 pmcb:ShelfOfferingMember 2019-05-01 2019-10-31 0001157075 pmcb:EmployeeOptionsMember 2019-05-01 2019-10-31 0001157075 us-gaap:StockOptionMember 2020-05-01 2020-10-31 0001157075 us-gaap:StockOptionMember 2020-04-30 0001157075 us-gaap:StockOptionMember 2020-10-31 0001157075 pmcb:UnvestedStockOptionsMember 2020-05-01 2020-10-31 0001157075 pmcb:UnvestedStockOptionsMember 2020-04-30 0001157075 pmcb:UnvestedStockOptionsMember 2020-10-31 0001157075 pmcb:Price1Member 2020-05-01 2020-10-31 0001157075 pmcb:Price2Member 2020-05-01 2020-10-31 0001157075 pmcb:Price3Member 2020-05-01 2020-10-31 0001157075 pmcb:Price4Member 2020-05-01 2020-10-31 0001157075 pmcb:Price5Member 2020-05-01 2020-10-31 0001157075 pmcb:Price6Member 2020-05-01 2020-10-31 0001157075 pmcb:Price7Member 2020-05-01 2020-10-31 0001157075 pmcb:Price8Member 2020-05-01 2020-10-31 0001157075 pmcb:Price9Member 2020-05-01 2020-10-31 0001157075 pmcb:Price10Member 2020-05-01 2020-10-31 0001157075 pmcb:Price11Member 2020-05-01 2020-10-31 0001157075 pmcb:Price12Member 2020-05-01 2020-10-31 0001157075 pmcb:Price13Member 2020-05-01 2020-10-31 0001157075 pmcb:Price14Member 2020-05-01 2020-10-31 0001157075 pmcb:Price15Member 2020-05-01 2020-10-31 0001157075 pmcb:Price16Member 2020-05-01 2020-10-31 0001157075 pmcb:Price17Member 2020-05-01 2020-10-31 0001157075 pmcb:Price18Member 2020-05-01 2020-10-31 0001157075 pmcb:Price19Member 2020-05-01 2020-10-31 0001157075 pmcb:Price20Member 2020-05-01 2020-10-31 0001157075 pmcb:Price21Member 2020-05-01 2020-10-31 0001157075 pmcb:Price22Member 2020-05-01 2020-10-31 0001157075 pmcb:Price1Member 2020-10-31 0001157075 pmcb:Price2Member 2020-10-31 0001157075 pmcb:Price3Member 2020-10-31 0001157075 pmcb:Price4Member 2020-10-31 0001157075 pmcb:Price5Member 2020-10-31 0001157075 pmcb:Price6Member 2020-10-31 0001157075 pmcb:Price7Member 2020-10-31 0001157075 pmcb:Price8Member 2020-10-31 0001157075 pmcb:Price9Member 2020-10-31 0001157075 pmcb:Price10Member 2020-10-31 0001157075 pmcb:Price11Member 2020-10-31 0001157075 pmcb:Price12Member 2020-10-31 0001157075 pmcb:Price13Member 2020-10-31 0001157075 pmcb:Price14Member 2020-10-31 0001157075 pmcb:Price15Member 2020-10-31 0001157075 pmcb:Price16Member 2020-10-31 0001157075 pmcb:Price17Member 2020-10-31 0001157075 pmcb:Price18Member 2020-10-31 0001157075 pmcb:Price19Member 2020-10-31 0001157075 pmcb:Price20Member 2020-10-31 0001157075 pmcb:Price21Member 2020-10-31 0001157075 pmcb:Price22Member 2020-10-31 0001157075 us-gaap:WarrantMember 2020-05-01 2020-10-31 0001157075 us-gaap:WarrantMember 2020-04-30 0001157075 us-gaap:WarrantMember 2020-10-31 0001157075 pmcb:Warrant1Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant2Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant3Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant4Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant5Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant6Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant7Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant8Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant9Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant10Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant11Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant12Member 2020-05-01 2020-10-31 0001157075 pmcb:Warrant13Member 2020-05-01 2020-10-31 0001157075 us-gaap:WarrantMember 2020-05-01 2020-10-31 0001157075 pmcb:Warrant1Member 2020-10-31 0001157075 pmcb:Warrant2Member 2020-10-31 0001157075 pmcb:Warrant3Member 2020-10-31 0001157075 pmcb:Warrant4Member 2020-10-31 0001157075 pmcb:Warrant5Member 2020-10-31 0001157075 pmcb:Warrant6Member 2020-10-31 0001157075 pmcb:Warrant7Member 2020-10-31 0001157075 pmcb:Warrant8Member 2020-10-31 0001157075 pmcb:Warrant9Member 2020-10-31 0001157075 pmcb:Warrant10Member 2020-10-31 0001157075 pmcb:Warrant11Member 2020-10-31 0001157075 pmcb:Warrant12Member 2020-10-31 0001157075 pmcb:Warrant13Member 2020-10-31 0001157075 us-gaap:WarrantMember 2020-10-31 0001157075 us-gaap:StockOptionMember pmcb:EmployeesMember 2020-08-01 2020-10-31 0001157075 us-gaap:StockOptionMember pmcb:EmployeesMember 2019-08-01 2019-10-31 0001157075 us-gaap:StockOptionMember pmcb:EmployeesMember 2020-05-01 2020-10-31 0001157075 us-gaap:StockOptionMember pmcb:EmployeesMember 2019-05-01 2019-10-31 0001157075 us-gaap:StockOptionMember pmcb:NonEmployeesMember 2020-05-01 2020-10-31 0001157075 us-gaap:StockOptionMember pmcb:NonEmployeesMember 2019-05-01 2019-10-31 0001157075 us-gaap:StockOptionMember pmcb:NonEmployeesMember 2020-08-01 2020-10-31 0001157075 us-gaap:StockOptionMember pmcb:NonEmployeesMember 2019-08-01 2019-10-31 0001157075 us-gaap:StockOptionMember pmcb:EmployeesMember 2020-10-31 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2019-05-01 2019-06-13 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2019-05-01 2019-07-15 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2019-05-01 2019-08-07 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-07-10 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-07-18 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-07-19 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-07-27 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-08-03 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-08-06 0001157075 us-gaap:WarrantMember pmcb:Aeon1Member 2020-05-01 2020-08-06 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-08-07 0001157075 us-gaap:WarrantMember pmcb:Aeon1Member 2020-05-01 2020-08-07 0001157075 us-gaap:WarrantMember pmcb:AeonMember 2020-05-01 2020-08-10 0001157075 pmcb:SGAustriaMember 2020-08-01 2020-10-31 0001157075 pmcb:SGAustriaMember 2020-05-01 2020-10-31 0001157075 pmcb:SGAustriaMember 2019-08-01 2019-10-31 0001157075 pmcb:SGAustriaMember 2019-05-01 2019-10-31 0001157075 pmcb:VinDeBonaMember 2020-08-01 2020-10-31 0001157075 pmcb:VinDeBonaMember 2020-05-01 2020-10-31 0001157075 pmcb:VinDeBonaMember 2019-08-01 2019-10-31 0001157075 pmcb:VinDeBonaMember 2019-05-01 2019-10-31 0001157075 pmcb:VinDeBonaMember pmcb:SalmonsMember 2020-05-01 2020-10-31 0001157075 us-gaap:StockOptionMember 2020-05-01 2020-10-31 0001157075 us-gaap:WarrantMember 2020-05-01 2020-10-31 0001157075 us-gaap:StockOptionMember 2019-05-01 2019-10-31 0001157075 us-gaap:WarrantMember 2019-05-01 2019-10-31 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares

0.0001

2490000000

0001157075 10-Q 2020-10-31 false --04-30 Q2 2021 Yes PharmaCyte Biotech, Inc.

1638637839

2334810405

1638637839

2334810405

3549427

1549427

2000000

224734 128376 56059 93995 128376 210909 0 13825 0 4414

234005899

458666667

66666667

70000000

693000000

137000000

2500000

1000000

5500000

3700000

250000

false false Yes NV 333-68008 2334810405 Non-accelerated Filer true

1638637839

2334810405

1186004505

1331871172

1875143738

1258171172

5088958

8276619

163864

108805062

-103858259

-21709

233482

113757416

-105692395

-21884

118600

133187

104966158

106654628

-100031371

-102232568

-13842

-20770

5039545

4534477

187515

125817

110818995

106059808

-104742203

-101165446

-19032

-20704

6245275

4999475

67320

104727

67320

104726

104727

67320

104726

19159

73553

250

100

550

370

40300

19059

311266

73183

40550

311816

-2201197

-1834136

-950192

-1067122

-6928

-175

2852

-66

2841850

325501

23401

45867

6667

7000

1833996

2795983

551333

318501

1857397

558000

6166638

8941359

-21709

-21884

-103858259

-105692395

108805062

113757416

163864

233482

1077680

664740

46282

21090

1031398

643650

28918

54110

816638

509422

185842

80118

6166638

8941359

5128992

7372

1572193

1037646

3812367

142785

94963

1267696383

1993895090

2309218013

1325086933

0.00

-2945

-677

1188

1757

677

-2201197

-1831191

-949515

-1067122

2201197

1831191

949515

1067122

827480

206362

88010

404728

225611

230168

88412

115454

158496

141341

69317

82854

899340

831432

552462

446146

90270

421888

151314

17940

-2208125

-1834311

-947340

-1067188

-6928

-175

2852

-66

56059

98409

72317

56059

126325

98409

72317

126325

1757

800

894861

3717404

515253

45061

-470192

2822543

-6928

-175

883501

4624171

883500

4699247

-1346765

-1801453

18307

-232139

42697

-105725

26128

-47822

209453

134640

385369

59709

NOTE 1 – NATURE OF BUSINESS   Overview   PharmaCyte Biotech, Inc. (“Company”) is a biotechnology company focused on developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, pancreatic cancer (“LAPC”), and Type 1 and insulin dependent Type 2 diabetes will be developed.   The Company is developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer prodrug into its cancer-killing form, encapsulating those cells using the Cell-in-a-Box® technology and placing those capsules in the body as close as possible to the tumor. In this way, the Company believes that when the cancer prodrug is administered to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient’s tumor may be optimized.   The Company is also examining ways to exploit the benefits of the Cell-in-a-Box® technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant; these constituents are of the class of compounds known as “cannabinoids.” Until the U.S. Food and Drug Administration (“FDA”) allows the Company to commence the clinical trial involving LAPC described in the Company’s recently filed Investigational New Drug Application (“IND”) for which the FDA has placed a clinical hold, the Company is not spending any further resources developing this program.   In addition, the Company is developing a therapy to delay the production and accumulation of malignant ascites fluid that results from many types of abdominal cancerous tumors. Malignant ascites fluid is secreted by abdominal cancerous tumors into the abdomen after the tumors have reached a certain stage of growth. This fluid contains cancer cells that can seed and form new tumors throughout the abdomen. This fluid accumulates in the abdominal cavity, causing swelling of the abdomen, severe breathing difficulties and extreme pain.   The Company is using its therapy for pancreatic cancer to determine if it can prevent or delay the production and accumulation of malignant ascites fluid. As with the Company’s Cannabis program, until the FDA allows it to commence the clinical trial involving LAPC described in its recently filed IND for which the FDA has placed a clinical hold, the Company is not spending any further resources developing this program.   The Company is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. The Company’s diabetes therapy consists of encapsulated genetically modified human liver cells and insulin-producing stem cells. The encapsulation for each type of cell will be done using the Cell-in-a-Box® technology. Implanting these cells in the body is designed to function as a bio-artificial pancreas for purposes of insulin production. As with the two previous programs, the Company is not spending any further resources developing this program until the FDA allows the Company to commence the clinical trial involving LAPC described in its recently filed IND for which the FDA has placed a clinical hold. However, related work at the University of Technology, Sydney (“UTS”) on the Melligen cells continues. Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body.   Finally, the Company has licensed (“Hai Kang License Agreement”) from Hai Kang Life Corporation (“Hai Kang”) the right to certain technology owned or controlled by Hai Kang related to SARS-Cov2 COVID-19 diagnostic kits (“Kits”). On November 19, 2020, the Company sent Hai Kang a letter terminating the Hai Kang License Agreement. See Note 13- Subsequent Events.   Clinical Hold   On September 1, 2020, the Company submitted an IND to the FDA for a planned Phase 2b clinical trial in LAPC. Shortly thereafter, the Company received Information Requests from the FDA related to the IND. The Company timely responded to all information requests.   On October 1, 2020, the Company received notice that the FDA had placed the IND on clinical hold.   On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted.   In order to lift the clinical hold, the FDA has informed the Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several topics, including data, manufacturing information and product release specifications.    In addition, the FDA requested that several items not related to the clinical hold be addressed through the submission of an IND amendment. Specifically, the FDA requested that the Company perform qualification studies for the drug substance filling step to ensure that the product remains sterile and stable during the filling process. The FDA also requested additional information, discussion and clarification on several other topics.   There has been no further communication with the FDA regarding the clinical hold.   The Company has assembled a scientific team to address the FDA requests related to the clinical hold.   See Management’s Discussion and Analysis of Financial Condition and Results of Operations-Clinical Hold for a further discussion of the clinical hold.   Impact of the COVID-19 Pandemic on the Company’s Operations   The coronavirus SARS-Cov2 pandemic (“COVID-19”) is causing significant, industry-wide delays in clinical trials. Although the Company is not yet in a clinical trial, the Company has filed an IND with the FDA to commence a clinical trial in LAPC. While the IND has been placed on clinical hold by the FDA, the Company has assessed the impact of COVID-19 on its operations. Currently, many clinical trials are being delayed due to COVID-19. There are numerous reasons for these delays. For example, patients have shown a reluctance to enroll or continue in a clinical trial due to fear of exposure to COVID-19 when they are in a hospital or doctor’s office. There are local, regional and state-wide orders and regulations restricting usual normal activity by people. These discourage and interfere with patient visits to a doctor’s office if the visit is not COVID-19 related. Healthcare providers and health systems are shifting their resources away from clinical trials toward the care of COVID-19 patients. The FDA and other healthcare providers are making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to COVID-19. As of the date of this Report on Form 10-Q (“Report”), the COVID-19 pandemic has had an impact upon the Company’s operations, although the Company believes that impact is not material. The impact primarily relates to delays in tasks associated with the preparation of the Company’s response to the clinical hold, including all preclinical studies. There may be further delays in generating responses to the requests from the FDA related to the clinical hold.   As a result of the COVID-19 pandemic, commencement of the Company’s planned clinical trial to treat LAPC may be delayed beyond the lifting of the clinical hold should that occur. Also, enrollment may be difficult for the reasons discussed above. In addition, after enrollment in the trial, if patients contract COVID-19 during their participation in the trial or are subject to isolation or shelter in place restrictions, this may cause them to drop out of our trial, miss scheduled therapy appointments or follow-up visits or otherwise fail to follow the trial protocol. If patients are unable to follow the trial protocol or if the trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the trial may be compromised or not be accepted by the FDA. This could further adversely impact or delay the Company’s clinical development program.   It is highly speculative in projecting the effects of COVID-19 on the Company’s clinical development program and the Company generally. The effects of COVID-19 quickly and dramatically change over time. Its evolution is difficult to predict, and no one is able to say with certainty when the pandemic will subside.   Company Background   The Company is a Nevada corporation incorporated in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The restructuring resulted in the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer and diabetes. In January 2015, the Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Principles of Consolidation and Basis of Presentation   The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) Bio Blue Bird AG; (ii) PharmaCyte Biotech Europe Limited; (iii) PharmaCyte Biotech Australia Pty. Ltd.; and (iv) Viridis Biotech, Inc. and are prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“Commission”). Intercompany balances and transactions are eliminated. The Company’s 14.5% investment in SG Austria is presented on the cost method of accounting.   Use of Estimates   The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates these estimates including those related to fair values of financial instruments, intangible assets, fair value of stock-based awards, income taxes and contingent liabilities, among others. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s Condensed Consolidated Financial Statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s condensed consolidated financial position and results of operations.   Intangible Assets   The Financial Accounting Standards Board ("FASB") standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year.   The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box® technology for $1,549,427 and the diabetes license for $2,000,000 for an aggregate total of $3,549,427.   These intangible assets have an indefinite life; therefore, they are not amortizable.   The Company concluded that there was no impairment of the carrying value of the intangibles for the six months ended October 31, 2020 and 2019.   Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment was identified or recorded during the six months ended October 31, 2020 and 2019.   Fair Value of Financial Instruments   For certain of the Company’s non-derivative financial instruments, including cash, accounts payable and accrued expenses, the carrying amount approximates fair value due to the short-term maturities of these instruments.   Accounting Standards Codification ("ASC") Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the condensed consolidated balance sheets for current liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%; text-align: justify">Level 1. Observable inputs such as quoted prices in active markets;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%; text-align: justify">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%; text-align: justify">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr> </table>   Income Taxes   Deferred taxes are calculated using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.   The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. The Company believes the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based on, among other things, an estimate of future taxable income in the U.S. and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against the Company’s net deferred income tax assets, the Company considers all available evidence, both positive and negative. Consistent with the Company’s policy, and because of the Company’s history of operating losses, the Company does not currently recognize the benefit of all its deferred tax assets, including tax loss carry forwards, which may be used to offset future taxable income. The Company continually assesses its ability to generate sufficient taxable income during future periods in which deferred tax assets may be realized. When the Company believes it is more-likely-than-not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in the Condensed Consolidated Statements of Operations.   The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more-likely-than-not to be sustained upon examination. Step two, measurement, is addressed only if a position is more-likely-than-not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more-likely-than-not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more-likely-than-not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more-likely-than-not standard is met, the issue is resolved with the taxing authority or the statute of limitations expires. Positions previously recognized are derecognized when the Company subsequently determines the position no longer is more-likely-than-not to be sustained. Evaluation of tax positions, their technical merits and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.   On March 27, 2020, Congress enacted the “Coronavirus Aid, Relief and Economic Security ("CARES") Act” to provide certain relief as a result of COVID-19. The Company maintains a full valuation allowance on its U.S. net deferred tax assets. Deferred tax asset remeasurement (tax expense) was offset by a net decrease in valuation allowance, that resulted in no impact on the Company's income tax expense. Therefore, the Company does not expect the provisions in the CARES Act will impact the Company’s Condensed Consolidated Financial Statements.   Research and Development   Research and development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in R&D and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established.   R&D expenses for the three and six months ended October 31, 2020 were $151,314 and $421,888, respectively, and for the three and six months ended October 31, 2019 were $17,940 and $90,270, respectively.   Stock-Based Compensation   The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future.   Concentration of Credit Risk   The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at a financial institution located in California. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. Uninsured balances aggregated approximately $3,439,000 and $618,000 at October 31, 2020 and April 30, 2020, respectively. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit risk on cash.   Foreign Currency Translation   The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters. All assets and liabilities of the Company’s foreign subsidiaries are translated at period-end exchange rates, while revenue and expenses are translated at average exchange rates prevailing during the period. Adjustments for foreign currency translation fluctuations are excluded from net loss and are included in other comprehensive loss. Gains and losses on short-term intercompany foreign currency transactions are recognized as incurred.   Going Concern   The accompanying Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern; however, the following conditions raise substantial doubt about the Company's ability to do so.   As of October 31, 2020, the Company has an accumulated deficit of $105,692,395 and incurred a net loss for the six months ended October 31, 2020 of $1,834,136. The Company requires substantial additional capital to finance its planned business operations and expects to incur operating losses in future periods due to the expenses related to the Company’s core businesses. The Company has not realized any revenue since it commenced doing business in the biotechnology sector, and there can be no assurance that it will be successful in generating revenues in the future in this sector. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.   For the six months ended October 31, 2020, funding was provided by investors to maintain and expand the Company’s operations. Sales of the Company’s common stock were made under an operative Form S-3 (“S-3”) allowing for offerings of up to $50 million dollars in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (“Securities Act”) or transactions structured as a public offering of a distinct block or blocks of the shares of the Company’s common stock. During the six months ended October 31, 2020, the Company continued to acquire funds through the Company’s S-3 pursuant to which the placement agent sells shares of common stock “at-the-market” in a program which is structured to provide up to $25 million to the Company less certain commissions pursuant to the S-3.   On August 13, 2020, the Company no longer met the eligibility requirements to use the S-3 to raise capital, and the Company ceased to use the S-3 to raise capital after that date. From May 1, 2020 through August 13, 2020 the Company raised capital of approximately $4.7 million in Block Trade transactions and “at-the-market” transactions.   Management determined that its plans to raise additional capital alleviate substantial doubt about the Company’s ability to continue as a going concern. The Company believes the cash on hand, the potential sales of unregistered shares of its common stock and any public offerings of common stock in which the Company may engage in will provide sufficient capital to meet the Company’s capital requirements and to fund the Company’s operations through December 31, 2021.   Recent Accounting Pronouncements   ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), was issued in June 2016. Under ASU 2016-13, existing guidance on reporting credit losses for trade and other receivables and available for sale debt securities will be replaced with a new forward-looking "expected loss" model that generally will result in the earlier recognition of allowances for losses. The Company’s adoption of ASU 2016-13 during the quarter ended July 31, 2020 did not result in an impact on the Company’s Condensed Consolidated Financial Statements. As part of the Company’s continuing assessment of the adequacy of AU 2016-13, there are no factors to be considered at this time, as the Company does not have an allowance for credit losses.   ASU No. 2019-12, Simplifying the Accounting for Income Taxes ("ASU 2019-12"), was issued in December 2019. Under ASU 2019-12, the accounting for income taxes is simplified by eliminating certain exceptions and implementing additional requirements which result in a more consistent application of ASC 740. The Company is currently in the process of evaluating the impact of adopting ASU 2019-12 in 2021, but it does not expect it to have a material impact on the Company’s Condensed Consolidated Financial Statements.

NOTE 3 – ACCRUED EXPENSES   Accrued expenses at October 31, 2020 and April 30, 2020 are summarized below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">April 30, 2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%; text-align: justify">Payroll related costs</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">462,781</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">435,577</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Director and Officer insurance financing</td> <td> </td> <td> </td> <td style="text-align: right">38,168</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">113,245</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; text-align: justify">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">8,473</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">267,816</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">509,422</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">816,638</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The Company financed the Director and Officer insurance policy. The term of the policy is from March 8, 2020 through March 8, 2021. The financing agreement has an interest rate of 4.25% per annum and requires eight monthly payments of $12,806. The unpaid balances as of October 31, 2020 and April 30, 2020 are $38,168 and $113,245, respectively, which are included in accrued expenses.

NOTE 7 – LEGAL PROCEEDINGS   The Company is not currently a party to any pending legal proceedings, material or otherwise. There are no legal proceedings to which any property of the Company is subject.

NOTE 10 - INCOME TAXES   The Company had no income tax expense for the six months ended October 31, 2020 and 2019, respectively. During the six months ended October 31, 2020 and 2019, the Company had a net operating loss (“NOL”) for each period which generated deferred tax assets for NOL carryforwards. The Company provided valuation allowances against the net deferred tax assets including the deferred tax assets for NOL carryforwards. Valuation allowances provided for the net deferred tax asset increased by approximately $355,000 and $449,000 for the six months ended October 31, 2020 and 2019, respectively.   There was no material difference between the effective tax rate and the projected blended statutory tax rate for the six months ended October 31, 2020 and 2019.   Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. Based on the assessment of all available evidence including, but not limited to, the Company’s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulations and healthcare reform initiatives and other risks normally associated with biotechnology companies, the Company has concluded that is more-likely-than-not that these operating loss carryforwards will not be realized. Accordingly, 100% of the deferred tax valuation allowance has been recorded against these assets at October 31, 2020.   The Company’s policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of the six months ended October 31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions.   See Note 10 of Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended April 30, 2020 for additional information regarding income taxes.

NOTE 11 – EARNINGS PER SHARE   Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares and potentially dilutive shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would be outstanding if the potentially dilutive securities had been issued. Potential shares of common stock outstanding principally include stock options and warrants. During the six months ended October 31, 2020 and 2019, the Company incurred losses. Accordingly, the effect of any common stock equivalent would be anti-dilutive during those periods and are not included in the calculation of diluted weighted average number of shares outstanding.   The table below sets forth the basic loss per share calculations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(950,192</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(1,067,122</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">2,309,218,013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,325,086,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Diluted weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">2,309,218,013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,325,086,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic and diluted loss per share</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(1,834,136</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(2,201,197</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">1,993,895,090</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,267,696,383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Diluted weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">1,993,895,090</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,267,696,383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic and diluted loss per share</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td></tr> </table>   The table below sets forth these potentially dilutive securities:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Excluded options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">69,200,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">85,650,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Excluded warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">82,256,821</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">48,056,822</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; text-align: justify">Total excluded options and warrants</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">151,456,821</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">133,706,822</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 12 – PREFERRED STOCK    The Company has authorized 10,000,000 shares of preferred stock, with a par value of $0.0001, of which one share has been designated as "Series A Preferred Stock". The one share of Series A Preferred Stock was issued on October 30, 2019 and repurchased by the Company on December 3, 2019. As of October 31, 2020, there are no shares of preferred stock issued and outstanding.   The description of the Series A Preferred Stock below is qualified in its entirety by reference to the Company’s Articles of Incorporation, as amended.   The Series A Preferred Stock has the following features:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%">There is one share of preferred stock designated as Series A Preferred Stock;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>•</td> <td style="text-align: justify">The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders of the Company having a right to vote on any matter plus one. The Certificate of Designations that designated the terms of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%; text-align: justify">The Company may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series A Preferred Stock; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>•</td> <td style="text-align: justify">The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation in any distributions to shareholders.</td></tr> </table>

Principles of Consolidation and Basis of Presentation   The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) Bio Blue Bird AG; (ii) PharmaCyte Biotech Europe Limited; (iii) PharmaCyte Biotech Australia Pty. Ltd.; and (iv) Viridis Biotech, Inc. and are prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“Commission”). Intercompany balances and transactions are eliminated. The Company’s 14.5% investment in SG Austria is presented on the cost method of accounting.

Use of Estimates   The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates these estimates including those related to fair values of financial instruments, intangible assets, fair value of stock-based awards, income taxes and contingent liabilities, among others. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s Condensed Consolidated Financial Statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s condensed consolidated financial position and results of operations.

Intangible Assets   The Financial Accounting Standards Board ("FASB") standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year.   The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box® technology for $1,549,427 and the diabetes license for $2,000,000 for an aggregate total of $3,549,427.   These intangible assets have an indefinite life; therefore, they are not amortizable.   The Company concluded that there was no impairment of the carrying value of the intangibles for the six months ended October 31, 2020 and 2019.

Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment was identified or recorded during the six months ended October 31, 2020 and 2019.

Fair Value of Financial Instruments   For certain of the Company’s non-derivative financial instruments, including cash, accounts payable and accrued expenses, the carrying amount approximates fair value due to the short-term maturities of these instruments.   Accounting Standards Codification ("ASC") Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the condensed consolidated balance sheets for current liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 3%">•</td> <td style="font: 12pt Times New Roman, Times, Serif; width: 94%; text-align: justify">Level 1. Observable inputs such as quoted prices in active markets;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%; text-align: justify">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">•</td> <td style="width: 94%; text-align: justify">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr> </table>

Research and Development   Research and development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in R&D and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established.   R&D expenses for the three and six months ended October 31, 2020 were $151,314 and $421,888, respectively, and for the three and six months ended October 31, 2019 were $17,940 and $90,270, respectively.

Stock-Based Compensation   The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future.

Concentration of Credit Risk   The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at a financial institution located in California. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. Uninsured balances aggregated approximately $3,439,000 and $618,000 at October 31, 2020 and April 30, 2020, respectively. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit risk on cash.

Foreign Currency Translation   The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters. All assets and liabilities of the Company’s foreign subsidiaries are translated at period-end exchange rates, while revenue and expenses are translated at average exchange rates prevailing during the period. Adjustments for foreign currency translation fluctuations are excluded from net loss and are included in other comprehensive loss. Gains and losses on short-term intercompany foreign currency transactions are recognized as incurred.

Recent Accounting Pronouncements   ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), was issued in June 2016. Under ASU 2016-13, existing guidance on reporting credit losses for trade and other receivables and available for sale debt securities will be replaced with a new forward-looking "expected loss" model that generally will result in the earlier recognition of allowances for losses. The Company’s adoption of ASU 2016-13 during the quarter ended July 31, 2020 did not result in an impact on the Company’s Condensed Consolidated Financial Statements. As part of the Company’s continuing assessment of the adequacy of AU 2016-13, there are no factors to be considered at this time, as the Company does not have an allowance for credit losses.   ASU No. 2019-12, Simplifying the Accounting for Income Taxes ("ASU 2019-12"), was issued in December 2019. Under ASU 2019-12, the accounting for income taxes is simplified by eliminating certain exceptions and implementing additional requirements which result in a more consistent application of ASC 740. The Company is currently in the process of evaluating the impact of adopting ASU 2019-12 in 2021, but it does not expect it to have a material impact on the Company’s Condensed Consolidated Financial Statements.

Accrued expenses at October 31, 2020 and April 30, 2020 are summarized below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">April 30, 2020</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 68%; text-align: justify">Payroll related costs</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">462,781</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">435,577</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Director and Officer insurance financing</td> <td> </td> <td> </td> <td style="text-align: right">38,168</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">113,245</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; text-align: justify">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">8,473</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">267,816</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">509,422</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">816,638</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the Company’s unvested restricted stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%">Unvested, at April 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">4,600,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">3,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(6,500,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Unvested, at October 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">1,600,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">0.3</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.0</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">92</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">91</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Expected term (years)</td> <td> </td> <td> </td> <td style="text-align: right">2.5</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.5</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> </table>

A summary of the Company’s stock option activity and related information for the six months ended October 31, 2020 is shown below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Options</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Weighted Average Exercise Price per Share</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value per Share</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 58%; text-align: justify">Outstanding, April 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">67,200,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Granted</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.02</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">–</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Exercised</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; text-align: justify">Outstanding, October 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">69,200,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">0.06</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.06</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Exercisable, October 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">67,700,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">0.06</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; text-align: justify">Vested and expected to vest</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">69,200,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt">$</td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">0.06</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">–</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the activity for unvested stock options during the six months ended October 31, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Options</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value per Share</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Unvested, April 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">6,200,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.05</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Granted</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.02</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Vested</td> <td> </td> <td> </td> <td style="text-align: right">(6,700,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">–</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; text-align: justify">Unvested, October 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">1,500,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes the outstanding stock options by exercise price at October 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life of Outstanding Options (years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercisable Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price of Exercisable Options</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.063</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">15,600,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">0.10</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.063</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">15,600,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.063</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.104</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,450,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.87</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.104</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,450,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.104</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0685</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0..50</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0685</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0685</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.058</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,450,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.24</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.058</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,450,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.058</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0734</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0..84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0734</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0734</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0729</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,800,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0729</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,800,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0729</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.089</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.71</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.089</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.089</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0553</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0553</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0553</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0558</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.30</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0558</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0558</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0534</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.85</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0534</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0534</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0539</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0539</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0539</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0683</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0683</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0683</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0649</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.47</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0649</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0649</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0495</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.03</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0495</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0495</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0380</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0380</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0380</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.75</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0404</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0370</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.83</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0370</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0370</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0340</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0340</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0340</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0408</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.51</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0408</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0408</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0240</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0240</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0240</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$</td> <td style="text-align: right">0.0247</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0247</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0247</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.0105</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.47</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0105</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0105</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td> </td> <td style="text-align: right">Total</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">69,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.32</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.06</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,700,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.06</td> <td> </td></tr> </table>

A summary of the Company’s warrant activity and related information for the six months ended October 31, 2020 is shown below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Outstanding, April 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">47,890,155</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.05</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Issued</td> <td> </td> <td> </td> <td style="text-align: right">34,366,666</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt; text-align: justify">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">–</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Outstanding, October 31, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">82,256,821</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.03</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; text-align: justify">Exercisable, October 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">82,256,821</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes additional information concerning warrants outstanding and exercisable at October 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Number of Warrant Shares Exercisable at April 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">Weighted Average Remaining Contractual Life (Years)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 34%">$0.12</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">17,000,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">0.19</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$0.065</td> <td> </td> <td> </td> <td style="text-align: right">769,231</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.13</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$0.0575</td> <td> </td> <td> </td> <td style="text-align: right">869,565</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.42</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$0.03</td> <td> </td> <td> </td> <td style="text-align: right">2,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.07</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$0.026</td> <td> </td> <td> </td> <td style="text-align: right">1,923,077</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.66</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$0.025</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.73</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$0.018</td> <td> </td> <td> </td> <td style="text-align: right">1,388,889</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$0.011</td> <td> </td> <td> </td> <td style="text-align: right">2,272,727</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$0.01</td> <td> </td> <td> </td> <td style="text-align: right">13,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.42</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$0.015</td> <td> </td> <td> </td> <td style="text-align: right">833,333</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td>$0.009</td> <td> </td> <td> </td> <td style="text-align: right">3,333,333</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.67</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$0.0075</td> <td> </td> <td> </td> <td style="text-align: right">15.666.666</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 1pt">$0.005</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">20,500,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right">4.13</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">82,256,821</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">3.28</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">0.03</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of October 31, 2020.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 75%; padding-bottom: 1pt; text-align: justify">2021</td> <td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; width: 1%">$</td> <td style="border-bottom: black 1pt solid; width: 20%; text-align: right">5,144</td> <td style="width: 1%; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,144</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The table below sets forth the basic loss per share calculations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(950,192</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(1,067,122</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">2,309,218,013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,325,086,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Diluted weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">2,309,218,013</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,325,086,933</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic and diluted loss per share</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Net loss</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(1,834,136</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">(2,201,197</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">1,993,895,090</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,267,696,383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: justify">Diluted weighted average number of shares outstanding</td> <td> </td> <td> </td> <td style="text-align: right">1,993,895,090</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,267,696,383</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Basic and diluted loss per share</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.00</td> <td>)</td></tr> </table>

The table below sets forth these potentially dilutive securities:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended October 31,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center">2020</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 72%; text-align: justify">Excluded options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">69,200,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">85,650,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: justify">Excluded warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">82,256,821</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">48,056,822</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="padding-bottom: 2.5pt; text-align: justify">Total excluded options and warrants</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; padding-bottom: 2.5pt; text-align: right">151,456,821</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">133,706,822</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

278150

24500

198150

70000

0.145

618000

3439000

4700000

884000

435577

462781

113245 38168 38168

267816

8473

March 8, 2020 through March 8, 2021

0.0425

8 monthly payments

12806

75200

2022-04-15

75200

monthly

4600000

1600000

1100000

500000

1100000

6200000

1500000

3500000

6500000

6700000

0.06

0.03

0.02

0.03

2000000

1200000

2500000

6600000

2000000

1000000

6600000

500000

5408

19212

12816

4701

11910

3306

104727

209453

3205

10561

15793

27435

4701

11851

9419

16448

5409

9608

67320

134640

708

2300

500000

0.003

0.020

0.92

0.91

P2Y6M

0.0000

67200000

69200000

15600000

10450000

600000

2450000

1200000

1800000

1200000

500000

9000000

1200000

1000000

500000

9000000

1200000

1000000

500000

9000000

1000000

500000

2000000

1200000

67700000

0.063

0.104

0.0685

0.058

0.0734

0.0729

0.089

0.0553

0.0558

0.0534

0.0539

0.0683

0.0649

0.0495

0.038

0.0404

0.037

0.034

0.0408

0.024

0.0247

0.0105

69200000

0.06

0.05

0.04

15600000

10450000

600000

2450000

1200000

1800000

1200000

500000

9000000

1200000

1000000

500000

9000000

1200000

1000000

500000

7500000

1000000

500000

0.02

0.06

0.06 0.06 0.02

P1Y3M26D

P1M6D

P10M14D

P6M0D

P1Y2M27D

P0Y10M3D

P1Y8M9D

P1Y8M16D

P11M19D

P1Y3M19D

P2Y10M6D

P1Y2M30D

P1Y3M29D

P1Y5M20D

P2Y0M11D

P3Y10M25D

P1Y9M0D

P1Y9M29D

P1Y11M19D

P2Y6M3D

P2Y2M30D

P2Y3M29D

P2Y5M20D

47890155

82256821

34366666 0

82256821

17000000

769231

869565

2500000

1923077

2000000

1388889

2272727

13200000

833333

3333333

15666666

20500000

82256821

0.05

0.03

0.01

0.03 0.03

P2M8D

P1Y1M16D

P1Y5M1D

P2Y0M26D

P2Y7M28D

P1Y8M23D

P2Y6M29D

P3Y

P4Y5M1D

P4Y5M20D

P3Y8M2D

P4Y8M26D

P4Y1M16D

P3Y3M11D

35410

P2M

0.0089

1338889 1944444 3500000 4100000 3500000 1333333 2500000 4500000 4100000 5000000 2500000 5500000 1333333

9000

12000

29000

18000

7000

13000

24000

29000

18000

13000

19000

7000

10000

74000

2400

21000

44000

2000

15000

0.145

5144

16660

12536

5384

7999

449000

355000

1267696383

1993895090

2309218013

1325086933

1267696383

1993895090

2309218013

1325086933

133706822

151456821

69200000

82256821

85650000

48056822

-2852

-66

2677

-2852

-6862

-66

2677

-6862

-950192

-1067122

-883944

-950192

-1134075

-1067122

-883944

-1134075

75076

NOTE 5 – COMMON STOCK TRANSACTIONS   A summary of the Company’s stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 and 2019 is as follows:    During the six months ended October 31, 2019, the Company issued 2,000,000 shares of common stock to four non-employee members of the Company’s Board of Directors (“Board”) pursuant to Director Letter Agreements (“DLAs”) with the Company for services relating to the prior year. The shares vested upon issuance and the Company recorded a non-cash expense of $0 and $0 and for the three and six months ended October 31, 2020, respectively, and $5,408 and $19,212 for the three and six months ended October 31, 2019, respectively.   Effective July 1, 2018, the Company issued 1,200,000 shares of common stock to a consultant. The term of the agreement is for twelve months. The shares vest monthly over a twelve-month period and are subject to the consultant providing services under the agreement. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $0 and $12,816 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares as of October 31, 2020 and 2019, respectively.   During the month of April 2019, two consultants were issued 2,500,000 shares of common stock pursuant to their consulting agreements. The term of the agreements is for twelve months which covered prior and current periods. The shares vest monthly over a twelve-month period and are subject to the consultants providing services under their respective consulting agreements. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $4,701 and $11,910 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares as of October 31, 2020 and 2019.   During the six months ended October 31, 2019, a consultant was issued 500,000 shares of common stock pursuant to his consulting agreement with the Company. The term of the consulting agreement is for twelve months which covered prior and current periods. The shares vest monthly over a twelve-month period and are subject to the consultant providing services under his consulting agreement. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $0 and $3,306 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares as of October 31, 2020 and 2019.   In January 2019, the Company awarded 6,600,000 shares of common stock to executive officers of the Company as part of their compensation agreements for 2019. These shares vest monthly over a twelve-month period and are subject to them continuing service under their compensation agreements. During the three and six months ended October 31, 2020, the Company recorded a non-cash compensation expense in the amount of $0 and $0, respectively, and $104,727 and $209,453 for the three and six months ended October 31, 2019, respectively. There were zero and 1,100,000 unvested shares as of October 31, 2020 and 2019, respectively.   During the six months ended October 31, 2019, four non-employee members of the Board were issued 2,000,000 shares of common stock pursuant to their DLAs with the Company. The shares were fully vested upon issuance. The Company recorded a non-cash expense of $3,205 and $10,561 for the three and six months ended October 31, 2020, respectively, and $15,793 and $27,435 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to these DLAs as of October 31, 2020 and 2019.   During the six months ended October 31, 2019, a consultant was issued 2,000,000 shares of common stock in respect of his services as the Chairman of the Company’s Medical and Scientific Advisory Board over a four-year period with their vesting subject to the consultant providing services to the Company. The Company recorded a non-cash consulting expense in the amount of $0 and $0 for the three and six months ended October 31, 2020, respectively, and $4,701 and $11,851 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to his compensation arrangement as of October 31, 2020 and 2019.   During the six months ended October 31, 2020, four non-employee members of the Board were issued 2,000,000 shares of common stock pursuant to their DLAs in respect of their service during that year. The shares were fully vested upon issuance. The Company recorded a non-cash expense of $9,419 and $16,448 for the three and six months ended October 31, 2020, respectively, and $0 and $0 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to such DLAs as of October 31, 2020.   During the six months ended October 31, 2020, four consultants were issued 1,000,000 shares of common stock pursuant to their consulting agreements with the Company. The terms of the agreements are for twelve months. The shares vest monthly over a twelve-month period and are subject to the consultants providing services under the consultant’s consulting agreements. The Company recorded a non-cash consulting expense in the amount of $5,409 and $9,608 for the three and six months ended October 31, 2020, respectively, and $0 and $0 for the three and six months ended October 31, 2019, respectively. There were 500,000 unvested shares remaining related to these consulting agreements as of October 31, 2020.   In January 2020, the Company awarded 6,600,000 shares of common stock to the executive officers of the Company as part of their compensation agreements. These shares vest monthly over a twelve-month period and are subject to them continuing service under their compensation agreements. During the three and six months ended October 31, 2020, the Company recorded a non-cash compensation expense in the amounts of $67,320 and $134,640, respectively. There were 1,100,000 unvested shares as of October 31, 2020.   During the six months ended October 31, 2020, a consultant was issued 500,000 shares of common stock in respect of his services as the Chairman of the Company’s Medical and Scientific Advisory Board with the vesting subject to the consultant providing services to the Company. The Company recorded a non-cash consulting expense in the amount of $708 and $708 for the three and six months ended October 31, 2020, respectively, and $0 and $0 for the three and six months ended October 31, 2019, respectively. There were zero unvested shares remaining related to his compensation arrangement as of October 31, 2020 and 2019.   All shares listed above were issued without registration under the Securities Act in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act.    During the six months ended October 31, 2020 and 2019, the Company sold and issued approximately 693 million and 137 million shares of common stock, respectively, at prices of approximately $0.01 per share pursuant to the Company’s S-3. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received net proceeds of approximately $4.7 million and $884,000 from the sale of these shares for the six months ended October 31, 2020 and 2019, respectively.   A summary of the Company’s unvested restricted stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 70%">Unvested, at April 30, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">4,600,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Unvested, at October 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 6 – STOCK OPTIONS AND WARRANTS   Stock Options   As of October 31, 2020, the Company had 69,200,000 outstanding stock options to its directors and executive officers (collectively, “Employee Options”) and consultants (“Non-Employee Options”).   During the six months ended October 31, 2020 and 2019, the Company granted 2,000,000 and 2,000,000 Employee Options, respectively.   The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended October 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 70%; text-align: justify">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">0.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">2.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table>   The Company’s computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For stock option grants issued during the six months ended October 31, 2020 and 2019, the Company used a calculated volatility for each grant. The Company lacks adequate information about the exercise behavior and therefore has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company’s stock options of five years with the average vesting term of two and one-half years for an average of 2.5 years. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life.   During the six months ended October 31, 2020 and 2019, the Company granted zero and 1,200,000 Non-Employee Options, respectively. During the three months ended October 31, 2020 and 2019, the Company granted zero and 1,200,000 Non-Employee Options, respectively.   A summary of the Company’s stock option activity and related information for the six months ended October 31, 2020 is shown below:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 55%; text-align: justify">Outstanding, April 30, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">67,200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding, October 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,200,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, October 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">67,700,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,200,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>    A summary of the activity for unvested stock options during the six months ended October 31, 2020 is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 70%; text-align: justify">Unvested, April 30, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">6,200,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Unvested, October 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company recorded $56,059 and $93,995 of stock-based compensation expense related to the issuance of Employee Options to certain executive officers and directors in exchange for services during the three months ended October 31, 2020 and 2019, respectively, and $128,376 and $210,909 during the six months ended October 31, 2020 and 2019, respectively. At October 31, 2020, there remained $35,410 of unrecognized compensation expense related to unvested Employee Options granted to executive officers and directors, to be recognized as expense over a weighted-average period of the remaining two months in the calendar year. The unvested options vest at 750,000 shares per month and are expected to be fully vested on December 31, 2020.   The Company recorded $0 and $4,414 of stock-based compensation related to the issuance of Non-Employee Options in exchange for services during the three months ended October 31, 2020 and 2019, respectively, and $0 and 13,825 during the six months ended October 31, 2020 and 2019, respectively. There were no unvested Non-Employee Options on October 31, 2020.   The following table summarizes the outstanding stock options by exercise price at October 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life of Outstanding Options (years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercisable Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price of Exercisable Options</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.063</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">15,600,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">0.10</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.063</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">15,600,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.063</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.104</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,450,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.87</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.104</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,450,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.104</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0685</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0685</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0685</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.058</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,450,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.24</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.058</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,450,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.058</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0734</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.84</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0734</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0734</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0729</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,800,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0729</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,800,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0729</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.089</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.71</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.089</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.089</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0553</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0553</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0553</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0558</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.30</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0558</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0558</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0534</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.85</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0534</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0534</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0539</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0539</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0539</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0683</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0683</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0683</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0649</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.47</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0649</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0649</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0495</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.03</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0495</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0495</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0380</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.90</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0380</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0380</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.75</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0404</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0370</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.83</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0370</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0370</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0340</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.97</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0340</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0340</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0408</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.51</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0408</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0408</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0240</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.25</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0240</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0240</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>$</td> <td style="text-align: right">0.0247</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0247</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0247</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right">0.0105</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.47</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0105</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.0105</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td> <td style="text-align: right">Total</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">69,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.32</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.06</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,700,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.06</td> <td> </td></tr> </table>   The aggregate intrinsic value of outstanding options as of October 31, 2020 was zero. This represents options whose exercise price was less than the closing fair market value of the Company’s common stock on October 31, 2020 of approximately $0.0089 per share.   Warrants   The warrants issued by the Company are equity-classified. The fair value of the warrants was recorded as additional paid-in-capital, and no further adjustments are made.   For stock warrants paid in consideration of services rendered by non-employees, the Company recognizes consulting expense in accordance with the requirements of ASC 505. Common Stock Purchase Warrants issued in conjunction with Block Trade transactions to Aeon Capital, Inc. (‘Aeon”) are accounted for in accordance with ASC 815-40, with the fair value recorded to additional paid-in capital and offsetting amounts recorded as equity issuance costs on the Condensed Consolidated Statement of Stockholders’ Equity.   Effective June 13, 2019, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,338,889 shares of common stock based upon the Block Trade transaction pursuant to the Company’s engagement agreement with Aeon dated February 22, 2018 (“Aeon Engagement Agreement”). The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $9,000. The warrants have a cashless exercise feature.   Effective July 15, 2019, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,944,444 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $12,000. The warrants have a cashless exercise feature.   Effective August 7, 2019, the Company issued two Common Stock Purchase Warrants to Aeon for two Block Trade transactions. The Company issued two warrants to purchase a total of 3,500,000 shares of common stock based on two Block Trades pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate value of these warrants to be approximately $12,000. The warrants have a cashless exercise feature.    Effective July 10, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 4,100,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $29,000. The warrants have a cashless exercise feature.   Effective July 18, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 3,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $18,000. The warrants have a cashless exercise feature.   Effective July 19, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,333,333 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $7,000. The warrants have a cashless exercise feature.   Effective July 27, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 2,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $13,000. The warrants have a cashless exercise feature.   Effective August 3, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 4,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $24,000. The warrants have a cashless exercise feature.   Effective August 6, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 4,100,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $29,000. The warrants have a cashless exercise feature.   Effective August 6, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 5,000,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $18,000. The warrants have a cashless exercise feature.   Effective August 7, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 2,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $13,000. The warrants have a cashless exercise feature.   Effective August 7, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 5,500,000 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $19,000. The warrants have a cashless exercise feature.   Effective August 10, 2020, the Company issued a Common Stock Purchase Warrant to Aeon for a Block Trade transaction. The Company issued a warrant to purchase 1,333,333 shares of common stock based upon the Block Trade pursuant to the Aeon Engagement Agreement. The Company classified these warrants as equity. The warrants have a term of five years with an exercise price of approximately $0.01 per warrant share. Using the Black-Scholes-Merton option pricing model, the Company determined the aggregate fair value of these warrants to be approximately $7,000. The warrants have a cashless exercise feature.   A summary of the Company’s warrant activity and related information for the six months ended October 31, 2020 is shown below:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 70%; text-align: justify">Outstanding, April 30, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">47,890,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,366,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Outstanding, October 31, 2020</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">82,256,821</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.03</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, October 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">82,256,821</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The following table summarizes additional information concerning warrants outstanding and exercisable at October 31, 2020:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 73%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Prices</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrant Shares Exercisable at April 30, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 20%; text-align: left">$0.12</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">17,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">0.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$0.065</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">769,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$0.0575</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">869,565</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$0.03</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$0.026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,923,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$0.025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$0.018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,388,889</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$0.011</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,272,727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$0.01</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$0.015</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">833,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">$0.009</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,333,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$0.0075</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15.666.666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">$0.005</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">4.13</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">82,256,821</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

NOTE 8 – RELATED PARTY TRANSACTIONS   The Company had the following related party transactions during the three and six months ended October 31, 2020 and 2019.   The Company owns 14.5% of the equity in SG Austria and is reported on the cost method of accounting. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand Company Ltd. The Company purchased products and services from these subsidiaries in the approximate amounts of $10,000 and $74,000 in the three and six months ended October 31, 2020, respectively, and $0 and $2,400 for the three and six months ended October 31, 2019, respectively.   In April 2014, the Company entered the Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Walter H. Günzburg (“Prof. Günzburg) and Dr. Brian Salmons (“Dr. Salmons”), both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes (Prof. Gunzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months, automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. The agreement has been automatically renewed annually. The amounts incurred for the three and six months ended October 31, 2020 were approximately $21,000 and $44,000, respectively, and $2,000 and $15,000 for the three and six months ended October 31, 2019, respectively. In addition, during the six months ended October 31, 2020 the Company issued 250,000 shares of common stock to Dr. Salmons to be a member of the Company’s Medical and Scientific Advisory Board. The Company recorded a noncash consulting expense of approximately $2,300 relating to this share issuance for the six months ended October 31, 2020.   During the year ended April 30, 2020, the Company issued one share of Series A Preferred Stock to the Chief Executive Officer of the Company for $1 pursuant to a Subscription Agreement. The Series A Preferred Stock is described in detail in Note 12 – Preferred Stock. The Board exercised its right to have the Company redeem the one share of Series A Preferred Stock. It is no longer issued and outstanding.

NOTE 9 – COMMITMENTS AND CONTINGENCIES   The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical product if regulatory approval for marketing of the product candidate is obtained.   Office Lease   Effective September 1, 2017, the Company entered into an office lease at 23046 Avenida de la Carlota, Suite 600, Laguna Hills, California (“Leased Premises”). The term of the lease is for 24 months and expired on August 31, 2019. In May 2019, the Company entered into an additional one-year lease for the Leased Premises, commencing upon the expiration of the term of the prior lease. The term of the lease expired on August 31, 2020.   On May 28, 2020, the Company entered into an additional six-month lease of the Leased Premises, commencing on September 1, 2020. The term of the new lease expires on February 28, 2021.   Rent expenses for these offices for the three months ended October 31, 2020 and 2019 were $5,384 and $7,999, respectively, and for the six months ended October 31, 2020 and 2019 were $12,536 and $16,660, respectively.   The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of October 31, 2020.   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify; padding-bottom: 1pt">2021</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">5,144</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Compensation Agreements   The Company entered into executive compensation agreements with its three executive officers in March 2015, each of which was amended in December 2015 and March 2017. Each agreement has a term of two years with automatic annual extensions thereafter unless the Company or the executive officer provides written notification of termination at least ninety days prior to the end of the term or subsequent extensions. The Company also entered a compensation agreement with a Board member in April 2015 which continued in effect until amended in May 2017.   In May 2017, the Company amended the compensation agreement with the Board members and the terms continue in effect until a member is no longer on the Board.   The Company has four independent directors. Each director receives the same compensation: (i) $12,500 in cash for each calendar quarter of service on the Board; (ii) 500,000 fully-paid, non-assessable shares of the Company’s restricted common stock (“Shares”) annually; and (iii) a five-year option to purchase 500,000 Shares annually at an exercise price equal to the fair market value of the Shares on the date of grant. The Shares and the option Shares fully vest on the date of the grants.

NOTE 13 – SUBSEQUENT EVENTS   On November 19, 2020, the Company sent Hai Kang a letter terminating the Hai Kang License Agreement. The Company did so out of concerns over the failure to timely obtain an FDA Emergency Use Authorization for the Kits and the efficacy of the Kits. The Company is no longer pursuing this endeavor.   On December 2, 2020, the Company entered into a six-month office lease extension commencing on March 1, 2021. The lease extension is for the office where the Company is currently located in Laguna Hills, California. The term of the new lease expires on August 31. 2021 and requires monthly lease payments of approximately $1,300.

NOTE 4 – SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM   On March 27, 2020, the CARES Act was enacted to provide financial aid to family and businesses impacted by COVID-19. The Company participated in the CARES Act, and on April 15, 2020, the Company entered into a note payable with a bank under the Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”) loan in the amount of $75,200. This loan payable matures on April 15, 2022 with a fixed interest rate of 1% per annum with interest deferred for six months. The PPP loan has an initial term of two years, is unsecured and guaranteed by the SBA. Under the terms of the PPP loan, the Company may apply for forgiveness of the amount due on the PPP loan. The Company used the proceeds from the PPP loan for qualifying expenses as defined in the PPP. The Company intends to apply for forgiveness of the PPP loan in accordance with the terms of the CARES Act. However, the Company cannot assure at this time that the PPP loan will be forgiven partially or in full. The outstanding PPP loan balance as of October 31, 2020 and April 30, 2020 was $75,200.

EX-101.SCH 7 pmcb-20201031.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 1. NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 3. ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 5. COMMON STOCK TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 6. STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 7. LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 8. RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 10. INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 11. EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 12. PREFERRED STOCK link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 13. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 3. ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 5. COMMON STOCK TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 11. EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 3. ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 3. ACCRUED EXPENSES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 5. COMMON STOCK TRANSACTIONS (Details - Nonvested Option activity) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 5. COMMON STOCK TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Option Assumptions) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Unvested Option activity) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Options by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Warrant activity) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Warrants by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - 8. RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - 10. INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - 11. EARNINGS PER SHARE (Details - per share calculation) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - 11. EARNINGS PER SHARE (Details - diluted shares) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pmcb-20201031_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 pmcb-20201031_def.xml XBRL DEFINITION FILE EX-101.LAB 10 pmcb-20201031_lab.xml XBRL LABEL FILE Award Type [Axis] Employee Options [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital Accumulated Deficit Other Comprehensive Income (Loss) Series A Preferred Stock Common Stock Legal Entity [Axis] SG Austria [Member] Indefinite-lived Intangible Assets [Axis] Cell-in-a-Box [Member] Diabetes License [Member] Sale of Stock [Axis] Block Trade [Member] Transaction Type [Axis] Director and Officer Insurance Restricted Stock [Member] Statement Class Of Stock [Axis] Related Party [Axis] Four Directors [Member] Director Letter Agreement [Member] Counterparty Name [Axis] A Consultant [Member] Consulting Agreement [Member] Two Consultants [Member] Consulting Agreements [Member] A Consultant [Member] Officers [Member] 2019 Compensation Agreement [Member] Four Nonemployees [Member] Medical And Scientific Advisory Board [Member] Four Nonemployee [Member] Four Consultants [Member] 2020 Compensation Agreement [Member] A Consultant [Member] Shelf Offering [Member] Options [Member] Unvested Stock Options [Member] Exercise Price Range [Axis] $0.063 [Member] $0.104 [Member] $0.0685 [Member] $0.058 [Member] $0.0734 [Member] $0.0729 [Member] $0.089 [Member] $0.0553 [Member] $0.0558 [Member] $0.0534 [Member] $0.0539 [Member] $0.0683 [Member] $0.0649 [Member] $0.0495 [Member] $0.038 [Member] $0.0404 [Member] $0.037 [Member] $0.034 [Member] $0.0408 [Member] $0.0240 [Member] $0.0247 [Member] $0.0105 [Member] DerivativeInstrumentRisk [Axis] Warrants [Member] $0.12 [Member] $0.065 [Member] $0.0575 [Member] $0.03 [Member] $0.026 [Member] $0.025 [Member] $0.018 [Member] $0.011 [Member] $0.01 [Member] $0.015 [Member] $0.009 [Member] $0.0075 [Member] $0.005 [Member] Employees [Member] Non-Employees [Member] Aeon [Member] Aeon [Member] Vin-de-Bona [Member] Dr. Salmons [Member] Antidilutive Securities [Axis] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Emerging Growth Entity Small Business Entity Shell Company Interactive Data Current? Incorporation State Entity File Number Statement of Financial Position [Abstract] ASSETS Current Assets: Cash Prepaid expenses and other current assets Total Current Assets Other assets: Intangibles Investment in SG Austria Other assets Total other assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Accrued expenses Current portion of Small Business Administration - Paycheck Protection Program loan Total current liabilities Long term liabilities: Small Business Administration - Paycheck Protection Program loan Total Liabilities Commitments and Contingencies (Notes 7 and 9) Stockholders' Equity Common stock, authorized: 2,490,000,000 shares, $0.0001 par value; 2,334,810,405 and 1,638,637,839 shares issued and outstanding as of October 31, 2020 and April 30, 2020, respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders' equity Total Liabilities and Stockholders' Equity Common stock, par value Common stock, authorized Common stock issued Common stock, outstanding Income Statement [Abstract] Revenues: Revenue Operating expenses: Research and development costs Compensation expense Director fees Legal and professional General and administrative Total operating expenses Loss from operations Other expenses: Interest expense Other expense Total other expenses Net loss Basic and diluted loss per share Weighted average shares outstanding basic and diluted Net Loss Other comprehensive income (loss): Foreign currency translation Other comprehensive income (loss) Comprehensive loss Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, value Shares issued for compensation, shares Shares issued for compensation, value Shares issued for services, shares Shares issued for services, value Shares issued for cash, net of issuance costs, shares Shares issued for cash, net of issuance costs, value Stock based compensation - options Foreign currency translation adjustment Net loss Ending balance, shares Ending balance, amount Statement of Stockholders' Equity [Abstract] Payment of stock issuance costs Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Shares issued for services Shares issued for compensation Stock-based compensation - options Change in assets and liabilities: (Increase) decrease in prepaid expenses and other current assets Increase (decrease) in accounts payable Increase (decrease) in accrued expenses Net cash used in operating activities Cash flows from investing activities: Net cash provided by (used in) investing activities Cash flows from financing activities: Payment of insurance financing loan EX-101.PRE 11 pmcb-20201031_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Oct. 31, 2020	Dec. 11, 2020
Cover [Abstract]
Entity Registrant Name	PharmaCyte Biotech, Inc.
Entity Central Index Key	0001157075
Document Type	10-Q
Document Period End Date	Oct. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--04-30
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		2,334,810,405
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Entity Current Reporting Status	Yes
Entity Emerging Growth	false
Entity Small Business	true
Entity Shell Company	false
Interactive Data Current?	Yes
Incorporation State	NV
Entity File Number	333-68008

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Current Assets:
Cash	$ 3,717,404	$ 894,861
Prepaid expenses and other current assets	94,963	142,785
Total Current Assets	3,812,367	1,037,646
Other assets:
Intangibles	3,549,427	3,549,427
Investment in SG Austria	1,572,193	1,572,193
Other assets	7,372	7,372
Total other assets	5,128,992	5,128,992
Total Assets	8,941,359	6,166,638
Current Liabilities:
Accounts payable	80,118	185,842
Accrued expenses	509,422	816,638
Current portion of Small Business Administration - Paycheck Protection Program loan	54,110	28,918
Total current liabilities	643,650	1,031,398
Long term liabilities:
Small Business Administration - Paycheck Protection Program loan	21,090	46,282
Total Liabilities	664,740	1,077,680
Commitments and Contingencies (Notes 7 and 9)
Stockholders' Equity
Common stock, authorized: 2,490,000,000 shares, $0.0001 par value; 2,334,810,405 and 1,638,637,839 shares issued and outstanding as of October 31, 2020 and April 30, 2020, respectively	233,482	163,864
Additional paid in capital	113,757,416	108,805,062
Accumulated deficit	(105,692,395)	(103,858,259)
Accumulated other comprehensive loss	(21,884)	(21,709)
Total stockholders' equity	8,276,619	5,088,958
Total Liabilities and Stockholders' Equity	$ 8,941,359	$ 6,166,638

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Oct. 31, 2020	Apr. 30, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	2,490,000,000	2,490,000,000
Common stock issued	2,334,810,405	1,638,637,839
Common stock, outstanding	2,334,810,405	1,638,637,839

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Revenues:
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development costs	151,314	17,940	421,888	90,270
Compensation expense	552,462	446,146	831,432	899,340
Director fees	69,317	82,854	141,341	158,496
Legal and professional	88,412	115,454	230,168	225,611
General and administrative	88,010	404,728	206,362	827,480
Total operating expenses	949,515	1,067,122	1,831,191	2,201,197
Loss from operations	(949,515)	(1,067,122)	(1,831,191)	(2,201,197)
Other expenses:
Interest expense	(677)	0	(1,757)	0
Other expense	0	0	(1,188)	0
Total other expenses	(677)	0	(2,945)	0
Net loss	$ (950,192)	$ (1,067,122)	$ (1,834,136)	$ (2,201,197)
Basic and diluted loss per share	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted average shares outstanding basic and diluted	2,309,218,013	1,325,086,933	1,993,895,090	1,267,696,383

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Income Statement [Abstract]
Net Loss	$ (950,192)	$ (1,067,122)	$ (1,834,136)	$ (2,201,197)
Other comprehensive income (loss):
Foreign currency translation	2,852	(66)	(175)	(6,928)
Other comprehensive income (loss)	2,852	(66)	(175)	(6,928)
Comprehensive loss	$ (947,340)	$ (1,067,188)	$ (1,834,311)	$ (2,208,125)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount before tax, after reclassification adjustments of other comprehensive income (loss).

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Series A Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Other Comprehensive Income (Loss)	Total
Beginning balance, shares at Apr. 30, 2019	0	1,186,004,505
Beginning balance, value at Apr. 30, 2019	$ 0	$ 118,600	$ 104,966,158	$ (100,031,371)	$ (13,842)	$ 5,039,545
Shares issued for compensation, shares
Shares issued for compensation, value			104,726			104,726
Shares issued for services, shares		5,500,000
Shares issued for services, value		$ 550	311,266			311,816
Shares issued for cash, net of issuance costs, shares		66,666,667
Shares issued for cash, net of issuance costs, value		$ 6,667	551,333			558,000
Stock based compensation - options			126,325			126,325
Foreign currency translation adjustment					(6,862)	(6,862)
Net loss				(1,134,075)		(1,134,075)
Ending balance, shares at Jul. 31, 2019	0	1,258,171,172
Ending balance, amount at Jul. 31, 2019	$ 0	$ 125,817	106,059,808	(101,165,446)	(20,704)	4,999,475
Beginning balance, shares at Apr. 30, 2019	0	1,186,004,505
Beginning balance, value at Apr. 30, 2019	$ 0	$ 118,600	104,966,158	(100,031,371)	(13,842)	5,039,545
Ending balance, shares at Oct. 31, 2019	1	1,331,871,172
Ending balance, amount at Oct. 31, 2019	$ 0	$ 133,187	106,654,628	(102,232,568)	(20,770)	4,534,477
Beginning balance, shares at Jul. 31, 2019	0	1,258,171,172
Beginning balance, value at Jul. 31, 2019	$ 0	$ 125,817	106,059,808	(101,165,446)	(20,704)	4,999,475
Shares issued for compensation, shares
Shares issued for compensation, value			104,727			104,727
Shares issued for services, shares		3,700,000
Shares issued for services, value		$ 370	73,183			73,553
Shares issued for cash, net of issuance costs, shares	1	70,000,000
Shares issued for cash, net of issuance costs, value		$ 7,000	318,501			325,501
Stock based compensation - options			98,409			98,409
Foreign currency translation adjustment					(66)	(66)
Net loss				(1,067,122)		(1,067,122)
Ending balance, shares at Oct. 31, 2019	1	1,331,871,172
Ending balance, amount at Oct. 31, 2019	$ 0	$ 133,187	106,654,628	(102,232,568)	(20,770)	4,534,477
Beginning balance, shares at Apr. 30, 2020	0	1,638,637,839
Beginning balance, value at Apr. 30, 2020	$ 0	$ 163,864	108,805,062	(103,858,259)	(21,709)	5,088,958
Shares issued for compensation, shares
Shares issued for compensation, value			67,320			67,320
Shares issued for services, shares		2,500,000
Shares issued for services, value		$ 250	40,300			40,550
Shares issued for cash, net of issuance costs, shares		234,005,899
Shares issued for cash, net of issuance costs, value		$ 23,401	1,833,996			1,857,397
Stock based compensation - options			72,317			72,317
Foreign currency translation adjustment					2,677	2,677
Net loss				(883,944)		(883,944)
Ending balance, shares at Jul. 31, 2020	0	1,875,143,738
Ending balance, amount at Jul. 31, 2020	$ 0	$ 187,515	110,818,995	(104,742,203)	(19,032)	6,245,275
Beginning balance, shares at Apr. 30, 2020	0	1,638,637,839
Beginning balance, value at Apr. 30, 2020	$ 0	$ 163,864	108,805,062	(103,858,259)	(21,709)	5,088,958
Ending balance, shares at Oct. 31, 2020	0	2,334,810,405
Ending balance, amount at Oct. 31, 2020	$ 0	$ 233,482	113,757,416	(105,692,395)	(21,884)	8,276,619
Beginning balance, shares at Jul. 31, 2020	0	1,875,143,738
Beginning balance, value at Jul. 31, 2020	$ 0	$ 187,515	110,818,995	(104,742,203)	(19,032)	6,245,275
Shares issued for compensation, shares
Shares issued for compensation, value			67,320			67,320
Shares issued for services, shares		1,000,000
Shares issued for services, value		$ 100	19,059			19,159
Shares issued for cash, net of issuance costs, shares		458,666,667
Shares issued for cash, net of issuance costs, value		$ 45,867	2,795,983			2,841,850
Stock based compensation - options			56,059			56,059
Foreign currency translation adjustment					(2,852)	(2,852)
Net loss				(950,192)		(950,192)
Ending balance, shares at Oct. 31, 2020	0	2,334,810,405
Ending balance, amount at Oct. 31, 2020	$ 0	$ 233,482	$ 113,757,416	$ (105,692,395)	$ (21,884)	$ 8,276,619

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)	3 Months Ended
	Oct. 31, 2020	Jul. 31, 2020	Oct. 31, 2019	Jul. 31, 2019
Statement of Stockholders' Equity [Abstract]
Payment of stock issuance costs	$ 278,150	$ 198,150	$ 24,500	$ 70,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Cash flows from operating activities:
Net loss	$ (1,834,136)	$ (2,201,197)
Adjustments to reconcile net loss to net cash used in operating activities:
Shares issued for services	59,709	385,369
Shares issued for compensation	134,640	209,453
Stock-based compensation - options	128,376	224,734
Change in assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets	47,822	(26,128)
Increase (decrease) in accounts payable	(105,725)	42,697
Increase (decrease) in accrued expenses	(232,139)	18,307
Net cash used in operating activities	(1,801,453)	(1,346,765)
Cash flows from investing activities:
Net cash provided by (used in) investing activities	0	0
Cash flows from financing activities:
Payment of insurance financing loan	(75,076)	0
Proceeds from sale of Series A Preferred Stock	0	1
Proceeds from sale of common stock, net of issuance costs	4,699,247	883,500
Net cash provided by financing activities	4,624,171	883,501
Effect of currency rate exchange on cash	(175)	(6,928)
Net increase (decrease) in cash	2,822,543	(470,192)
Cash at beginning of the period	894,861	515,253
Cash at end of the period	3,717,404	45,061
Supplemental disclosures of cash flows information:
Cash paid during the periods for income taxes	800	800
Cash paid during the periods for interest	$ 1,757	$ 0

XML 20 R9.htm IDEA: XBRL DOCUMENT

1. NATURE OF BUSINESS

6 Months Ended

Oct. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF BUSINESS

NOTE 1 – NATURE OF BUSINESS

Overview

Clinical Hold

On October 1, 2020, the Company received notice that the FDA had placed the IND on clinical hold.

On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted.

There has been no further communication with the FDA regarding the clinical hold.

The Company has assembled a scientific team to address the FDA requests related to the clinical hold.

See Management’s Discussion and Analysis of Financial Condition and Results of Operations-Clinical Hold for a further discussion of the clinical hold.

Impact of the COVID-19 Pandemic on the Company’s Operations

Company Background

XML 21 R10.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

Use of Estimates

Intangible Assets

The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box^®technology for $1,549,427 and the diabetes license for $2,000,000 for an aggregate total of $3,549,427.

These intangible assets have an indefinite life; therefore, they are not amortizable.

The Company concluded that there was no impairment of the carrying value of the intangibles for the six months ended October 31, 2020 and 2019.

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

•

Level 1. Observable inputs such as quoted prices in active markets;

•

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Income Taxes

Research and Development

Stock-Based Compensation

Concentration of Credit Risk

Foreign Currency Translation

Going Concern

Recent Accounting Pronouncements

XML 22 R11.htm IDEA: XBRL DOCUMENT

3. ACCRUED EXPENSES

6 Months Ended

Oct. 31, 2020

Payables and Accruals [Abstract]

ACCRUED EXPENSES

NOTE 3 – ACCRUED EXPENSES

Accrued expenses at October 31, 2020 and April 30, 2020 are summarized below:

	October 31, 2020		April 30, 2020
Payroll related costs	$	462,781	$	435,577
Director and Officer insurance financing		38,168		113,245
Other		8,473		267,816
Total	$	509,422	$	816,638

XML 23 R12.htm IDEA: XBRL DOCUMENT

4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM

6 Months Ended

Oct. 31, 2020

Debt Disclosure [Abstract]

SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM

NOTE 4 – SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM

XML 24 R13.htm IDEA: XBRL DOCUMENT

5. COMMON STOCK TRANSACTIONS

6 Months Ended

Oct. 31, 2020

Equity [Abstract]

COMMON STOCK TRANSACTIONS

NOTE 5 – COMMON STOCK TRANSACTIONS

A summary of the Company’s stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 and 2019 is as follows:

All shares listed above were issued without registration under the Securities Act in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act.

A summary of the Company’s unvested restricted stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 are as follows:

	Shares			Weighted Average Grant Date Fair Value

Unvested, at April 30, 2020		4,600,000		$	0.06
Granted		3,500,000			0.02
Vested		(6,500,000	)		0.03
Forfeited		–			–

Unvested, at October 31, 2020		1,600,000		$	0.03

XML 25 R14.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS

6 Months Ended

Oct. 31, 2020

Share-based Payment Arrangement [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE 6 – STOCK OPTIONS AND WARRANTS

Stock Options

During the six months ended October 31, 2020 and 2019, the Company granted 2,000,000 and 2,000,000 Employee Options, respectively.

The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions:

	Six Months Ended October 31,
	2020			2019
Risk-free interest rate		0.3	%		2.0	%
Expected volatility		92	%		91	%
Expected term (years)		2.5			2.5
Expected dividend yield		0.00	%		0.00	%

A summary of the Company’s stock option activity and related information for the six months ended October 31, 2020 is shown below:

	Options		Weighted Average Exercise Price per Share		Weighted Average Grant Date Fair Value per Share

Outstanding, April 30, 2020		67,200,000	$	0.06	$	0.06
Granted		2,000,000		0.02		0.02
Forfeited		–		–		–
Exercised		–		–		–
Outstanding, October 31, 2020		69,200,000	$	0.06	$	0.06
Exercisable, October 31, 2020		67,700,000	$	0.06	$	–
Vested and expected to vest		69,200,000	$	0.06	$	–

A summary of the activity for unvested stock options during the six months ended October 31, 2020 is as follows:

	Options			Weighted Average Grant Date Fair Value per Share

Unvested, April 30, 2020		6,200,000		$	0.05
Granted		2,000,000			0.02
Vested		(6,700,000	)		–
Forfeited		–			–
Unvested, October 31, 2020		1,500,000		$	0.04

The following table summarizes the outstanding stock options by exercise price at October 31, 2020:

Exercise Price		Number of Options Outstanding		Weighted Average Remaining Contractual Life of Outstanding Options (years)		Weighted Average Exercisable Price		Number of Options Exercisable		Weighted Average Exercise Price of Exercisable Options
$	0.063		15,600,000		0.10	$	0.063		15,600,000	$	0.063
$	0.104		10,450,000		0.87	$	0.104		10,450,000	$	0.104
$	0.0685		600,000		0.50	$	0.0685		600,000	$	0.0685
$	0.058		2,450,000		1.24	$	0.058		2,450,000	$	0.058
$	0.0734		1,200,000		0.84	$	0.0734		1,200,000	$	0.0734
$	0.0729		1,800,000		1.69	$	0.0729		1,800,000	$	0.0729
$	0.089		1,200,000		1.71	$	0.089		1,200,000	$	0.089
$	0.0553		500,000		0.97	$	0.0553		500,000	$	0.0553
$	0.0558		9,000,000		1.30	$	0.0558		9,000,000	$	0.0558
$	0.0534		1,200,000		2.85	$	0.0534		1,200,000	$	0.0534
$	0.0539		1,000,000		1.25	$	0.0539		1,000,000	$	0.0539
$	0.0683		500,000		1.33	$	0.0683		500,000	$	0.0683
$	0.0649		500,000		1.47	$	0.0649		500,000	$	0.0649
$	0.0495		9,000,000		2.03	$	0.0495		9,000,000	$	0.0495
$	0.0380		1,200,000		3.90	$	0.0380		1,200,000	$	0.0380
$	0.0404		1,000,000		1.75	$	0.0404		1,000,000	$	0.0404
$	0.0370		500,000		1.83	$	0.0370		500,000	$	0.0370
$	0.0340		500,000		1.97	$	0.0340		500,000	$	0.0340
$	0.0408		9,000,000		2.51	$	0.0408		7,500,000	$	0.0408
$	0.0240		1,000,000		2.25	$	0.0240		1,000,000	$	0.0240
$	0.0247		500,000		2.33	$	0.0247		500,000	$	0.0247
$	0.0105		500,000		2.47	$	0.0105		500,000	$	0.0105
	Total		69,200,000		1.32	$	0.06		67,700,000	$	0.06

Warrants

The warrants issued by the Company are equity-classified. The fair value of the warrants was recorded as additional paid-in-capital, and no further adjustments are made.

A summary of the Company’s warrant activity and related information for the six months ended October 31, 2020 is shown below:

	Warrants		Weighted Average Exercise Price
Outstanding, April 30, 2020		47,890,155	$	0.05
Issued		34,366,666		0.01
Expired		–		–
Outstanding, October 31, 2020		82,256,821		0.03
Exercisable, October 31, 2020		82,256,821	$	0.03

The following table summarizes additional information concerning warrants outstanding and exercisable at October 31, 2020:

Exercise Prices	Number of Warrant Shares Exercisable at April 30, 2020		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price

$0.12		17,000,000		0.19
$0.065		769,231		1.13
$0.0575		869,565		1.42
$0.03		2,500,000		2.07
$0.026		1,923,077		2.66
$0.025		2,000,000		1.73
$0.018		1,388,889		2.58
$0.011		2,272,727		3.00
$0.01		13,200,000		4.42
$0.015		833,333		4.47
$0.009		3,333,333		3.67
$0.0075		15.666.666		4.74
$0.005		20,500,000		4.13
		82,256,821		3.28	$	0.03

XML 26 R15.htm IDEA: XBRL DOCUMENT

7. LEGAL PROCEEDINGS

6 Months Ended

Oct. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

LEGAL PROCEEDINGS

NOTE 7 – LEGAL PROCEEDINGS

The Company is not currently a party to any pending legal proceedings, material or otherwise. There are no legal proceedings to which any property of the Company is subject.

XML 27 R16.htm IDEA: XBRL DOCUMENT

8. RELATED PARTY TRANSACTIONS

6 Months Ended

Oct. 31, 2020

RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

The Company had the following related party transactions during the three and six months ended October 31, 2020 and 2019.

XML 28 R17.htm IDEA: XBRL DOCUMENT

9. COMMITMENTS AND CONTINGENCIES

6 Months Ended

Oct. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 9 – COMMITMENTS AND CONTINGENCIES

Office Lease

On May 28, 2020, the Company entered into an additional six-month lease of the Leased Premises, commencing on September 1, 2020. The term of the new lease expires on February 28, 2021.

The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of October 31, 2020.

	Amount
2021	$	5,144
	$	5,144

Compensation Agreements

In May 2017, the Company amended the compensation agreement with the Board members and the terms continue in effect until a member is no longer on the Board.

XML 29 R18.htm IDEA: XBRL DOCUMENT

10. INCOME TAXES

6 Months Ended

Oct. 31, 2020

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 10 - INCOME TAXES

There was no material difference between the effective tax rate and the projected blended statutory tax rate for the six months ended October 31, 2020 and 2019.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

11. EARNINGS PER SHARE

6 Months Ended

Oct. 31, 2020

Earnings Per Share [Abstract]

EARNINGS PER SHARE

NOTE 11 – EARNINGS PER SHARE

The table below sets forth the basic loss per share calculations:

	Three Months Ended October 31,
	2020			2019
Net loss	$	(950,192	)	$	(1,067,122	)
Basic weighted average number of shares outstanding		2,309,218,013			1,325,086,933
Diluted weighted average number of shares outstanding		2,309,218,013			1,325,086,933
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)

	Six Months Ended October 31,
	2020			2019
Net loss	$	(1,834,136	)	$	(2,201,197	)
Basic weighted average number of shares outstanding		1,993,895,090			1,267,696,383
Diluted weighted average number of shares outstanding		1,993,895,090			1,267,696,383
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)

The table below sets forth these potentially dilutive securities:

	Six Months Ended October 31,
	2020		2019
Excluded options		69,200,000		85,650,000
Excluded warrants		82,256,821		48,056,822
Total excluded options and warrants		151,456,821		133,706,822

XML 31 R20.htm IDEA: XBRL DOCUMENT

12. PREFERRED STOCK

6 Months Ended

Oct. 31, 2020

Equity [Abstract]

PREFERRED STOCK

NOTE 12 – PREFERRED STOCK

The description of the Series A Preferred Stock below is qualified in its entirety by reference to the Company’s Articles of Incorporation, as amended.

The Series A Preferred Stock has the following features:

	•	There is one share of preferred stock designated as Series A Preferred Stock;

	•	The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders of the Company having a right to vote on any matter plus one. The Certificate of Designations that designated the terms of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock;

	•	The Company may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series A Preferred Stock; and

	•	The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation in any distributions to shareholders.

XML 32 R21.htm IDEA: XBRL DOCUMENT

13. SUBSEQUENT EVENTS

6 Months Ended

Oct. 31, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 13 – SUBSEQUENT EVENTS

XML 33 R22.htm IDEA: XBRL DOCUMENT

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Oct. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation

Use of Estimates

Use of Estimates

Intangible Assets

Intangible Assets

The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box^®technology for $1,549,427 and the diabetes license for $2,000,000 for an aggregate total of $3,549,427.

These intangible assets have an indefinite life; therefore, they are not amortizable.

The Company concluded that there was no impairment of the carrying value of the intangibles for the six months ended October 31, 2020 and 2019.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Fair value of Financial Instruments

Fair Value of Financial Instruments

•

Level 1. Observable inputs such as quoted prices in active markets;

•

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Income Taxes

Income Taxes

Research and Development

Research and Development

Stock-Based Compensation

Stock-Based Compensation

Concentration of Credit Risk

Concentration of Credit Risk

Foreign Currency Translation

Foreign Currency Translation

Going Concern

Going Concern

Recent accounting pronouncements

Recent Accounting Pronouncements

XML 34 R23.htm IDEA: XBRL DOCUMENT

3. ACCRUED EXPENSES (Tables)

6 Months Ended

Oct. 31, 2019

Payables and Accruals [Abstract]

Accrued expenses

Accrued expenses at October 31, 2020 and April 30, 2020 are summarized below:

	October 31, 2020		April 30, 2020
Payroll related costs	$	462,781	$	435,577
Director and Officer insurance financing		38,168		113,245
Other		8,473		267,816
Total	$	509,422	$	816,638

XML 35 R24.htm IDEA: XBRL DOCUMENT

5. COMMON STOCK TRANSACTIONS (Tables)

6 Months Ended

Oct. 31, 2020

Equity [Abstract]

Schedule of non-vested restricted stock activity

A summary of the Company’s unvested restricted stock activity and related weighted average grant date fair value information for the six months ended October 31, 2020 are as follows:

	Shares			Weighted Average Grant Date Fair Value

Unvested, at April 30, 2020		4,600,000		$	0.06
Granted		3,500,000			0.02
Vested		(6,500,000	)		0.03
Forfeited		–			–

Unvested, at October 31, 2020		1,600,000		$	0.03

XML 36 R25.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Tables)

6 Months Ended

Oct. 31, 2020

Stock option activity

A summary of the Company’s stock option activity and related information for the six months ended October 31, 2020 is shown below:

	Options		Weighted Average Exercise Price per Share		Weighted Average Grant Date Fair Value per Share

Outstanding, April 30, 2020		67,200,000	$	0.06	$	0.06
Granted		2,000,000		0.02		0.02
Forfeited		–		–		–
Exercised		–		–		–
Outstanding, October 31, 2020		69,200,000	$	0.06	$	0.06
Exercisable, October 31, 2020		67,700,000	$	0.06	$	–
Vested and expected to vest		69,200,000	$	0.06	$	–

Unvested stock option activity

A summary of the activity for unvested stock options during the six months ended October 31, 2020 is as follows:

	Options			Weighted Average Grant Date Fair Value per Share

Unvested, April 30, 2020		6,200,000		$	0.05
Granted		2,000,000			0.02
Vested		(6,700,000	)		–
Forfeited		–			–
Unvested, October 31, 2020		1,500,000		$	0.04

Schedule of options by exercise price

The following table summarizes the outstanding stock options by exercise price at October 31, 2020:

Exercise Price		Number of Options Outstanding		Weighted Average Remaining Contractual Life of Outstanding Options (years)		Weighted Average Exercisable Price		Number of Options Exercisable		Weighted Average Exercise Price of Exercisable Options
$	0.063		15,600,000		0.10	$	0.063		15,600,000	$	0.063
$	0.104		10,450,000		0.87	$	0.104		10,450,000	$	0.104
$	0.0685		600,000		0..50	$	0.0685		600,000	$	0.0685
$	0.058		2,450,000		1.24	$	0.058		2,450,000	$	0.058
$	0.0734		1,200,000		0..84	$	0.0734		1,200,000	$	0.0734
$	0.0729		1,800,000		1.69	$	0.0729		1,800,000	$	0.0729
$	0.089		1,200,000		1.71	$	0.089		1,200,000	$	0.089
$	0.0553		500,000		0.97	$	0.0553		500,000	$	0.0553
$	0.0558		9,000,000		1.30	$	0.0558		9,000,000	$	0.0558
$	0.0534		1,200,000		2.85	$	0.0534		1,200,000	$	0.0534
$	0.0539		1,000,000		1.25	$	0.0539		1,000,000	$	0.0539
$	0.0683		500,000		1.33	$	0.0683		500,000	$	0.0683
$	0.0649		500,000		1.47	$	0.0649		500,000	$	0.0649
$	0.0495		9,000,000		2.03	$	0.0495		9,000,000	$	0.0495
$	0.0380		1,200,000		3.90	$	0.0380		1,200,000	$	0.0380
$	0.0404		1,000,000		1.75	$	0.0404		1,000,000	$	0.0404
$	0.0370		500,000		1.83	$	0.0370		500,000	$	0.0370
$	0.0340		500,000		1.97	$	0.0340		500,000	$	0.0340
$	0.0408		9,000,000		2.51	$	0.0408		7,500,000	$	0.0408
$	0.0240		1,000,000		2.25	$	0.0240		1,000,000	$	0.0240
$	0.0247		500,000		2.33	$	0.0247		500,000	$	0.0247
$	0.0105		500,000		2.47	$	0.0105		500,000	$	0.0105
	Total		69,200,000		1.32	$	0.06		67,700,000	$	0.06

Warrant activity

A summary of the Company’s warrant activity and related information for the six months ended October 31, 2020 is shown below:

	Warrants		Weighted Average Exercise Price
Outstanding, April 30, 2020		47,890,155	$	0.05
Issued		34,366,666		0.01
Expired		–		–
Outstanding, October 31, 2020		82,256,821		0.03
Exercisable, October 31, 2020		82,256,821	$	0.03

Schedule of warrants outstanding and exercisable

The following table summarizes additional information concerning warrants outstanding and exercisable at October 31, 2020:

Exercise Prices	Number of Warrant Shares Exercisable at April 30, 2020		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price

$0.12		17,000,000		0.19
$0.065		769,231		1.13
$0.0575		869,565		1.42
$0.03		2,500,000		2.07
$0.026		1,923,077		2.66
$0.025		2,000,000		1.73
$0.018		1,388,889		2.58
$0.011		2,272,727		3.00
$0.01		13,200,000		4.42
$0.015		833,333		4.47
$0.009		3,333,333		3.67
$0.0075		15.666.666		4.74
$0.005		20,500,000		4.13
		82,256,821		3.28	$	0.03

Employee Options [Member]

Assumptions

The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions:

	Six Months Ended October 31,
	2020			2019
Risk-free interest rate		0.3	%		2.0	%
Expected volatility		92	%		91	%
Expected term (years)		2.5			2.5
Expected dividend yield		0.00	%		0.00	%

XML 37 R26.htm IDEA: XBRL DOCUMENT

9. COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Oct. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum rental payments for operating leases

The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of October 31, 2020.

	Amount
2021	$	5,144
	$	5,144

XML 38 R27.htm IDEA: XBRL DOCUMENT

11. EARNINGS PER SHARE (Tables)

6 Months Ended

Oct. 31, 2020

Earnings Per Share [Abstract]

Earnings per share calculations

The table below sets forth the basic loss per share calculations:

	Three Months Ended October 31,
	2020			2019
Net loss	$	(950,192	)	$	(1,067,122	)
Basic weighted average number of shares outstanding		2,309,218,013			1,325,086,933
Diluted weighted average number of shares outstanding		2,309,218,013			1,325,086,933
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)

	Six Months Ended October 31,
	2020			2019
Net loss	$	(1,834,136	)	$	(2,201,197	)
Basic weighted average number of shares outstanding		1,993,895,090			1,267,696,383
Diluted weighted average number of shares outstanding		1,993,895,090			1,267,696,383
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)

Schedule of potentially dilutive securities

The table below sets forth these potentially dilutive securities:

	Six Months Ended October 31,
	2020		2019
Excluded options		69,200,000		85,650,000
Excluded warrants		82,256,821		48,056,822
Total excluded options and warrants		151,456,821		133,706,822

XML 39 R28.htm IDEA: XBRL DOCUMENT

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Apr. 30, 2020
Intangible assets	$ 3,549,427		$ 3,549,427		$ 3,549,427
Impairment of intangible assets			0	$ 0
Research and development costs	151,314	$ 17,940	421,888	90,270
Uninsured cash balances	3,439,000		3,439,000		618,000
Accumulated deficit	(105,692,395)		(105,692,395)		$ (103,858,259)
Net loss	(950,192)	$ (1,067,122)	(1,834,136)	$ (2,201,197)
Block Trade [Member]
Proceeds from the sale of equity			4,700,000
Cell-in-a-Box [Member]
Intangible assets	1,549,427		1,549,427
Diabetes License [Member]
Intangible assets	$ 2,000,000		$ 2,000,000
SG Austria [Member]
Percentage investment in SG Austria	14.50%		14.50%

XML 40 R29.htm IDEA: XBRL DOCUMENT

3. ACCRUED EXPENSES (Details) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Payables and Accruals [Abstract]
Payroll related costs	$ 462,781	$ 435,577
Director and Officer insurance financing	38,168	113,245
Other	8,473	267,816
Total	$ 509,422	$ 816,638

XML 41 R30.htm IDEA: XBRL DOCUMENT

3. ACCRUED EXPENSES (Details Narrative) - USD ($)	6 Months Ended
3. ACCRUED EXPENSES (Details Narrative) - USD ($)	Oct. 31, 2020	Apr. 30, 2020
Director and Officer insurance financing	$ 38,168	$ 113,245
Director and Officer Insurance
Director and Officer insurance financing	$ 38,168
Policy period	March 8, 2020 through March 8, 2021
Financed interest rate	4.25%
Payment period	8 monthly payments
Payment amount	$ 12,806

XML 42 R31.htm IDEA: XBRL DOCUMENT

4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM (Details Narrative)	6 Months Ended
	Oct. 31, 2020 USD ($)
Debt Disclosure [Abstract]
Proceeds from loans	$ 75,200
Notes payable maturity date	Apr. 15, 2022
Loan payable outstanding	$ 75,200
Payment frequency	monthly

XML 43 R32.htm IDEA: XBRL DOCUMENT

5. COMMON STOCK TRANSACTIONS (Details - Nonvested Option activity) - Restricted Stock [Member]	6 Months Ended
	Oct. 31, 2020 $ / shares shares
Options Outstanding
Beginning balance \| shares	4,600,000
Granted \| shares	3,500,000
Vested \| shares	(6,500,000)
Forfeited \| shares	0
Ending balance \| shares	1,600,000
Weighted Average Grant Date Fair Value
Beginning balance \| $ / shares	$ 0.06
Granted \| $ / shares	0.02
Vested \| $ / shares	0.03
Forfeited \| $ / shares
Ending balance \| $ / shares	$ 0.03

XML 44 R33.htm IDEA: XBRL DOCUMENT

5. COMMON STOCK TRANSACTIONS (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Jul. 01, 2018	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Jan. 31, 2020	Apr. 30, 2019
Shelf Offering [Member]
Stock issued new, shares				693,000,000	137,000,000
Proceeds from sale of equity				$ 4,700,000	$ 884,000
Common Stock [Member] \| Director Letter Agreement [Member] \| Four Nonemployees [Member]
Stock issued for compensation, shares					2,000,000
Stock based compensation expense		$ 3,205	$ 15,793	$ 10,561	$ 27,435
Unvested shares		0	0	0	0
Common Stock [Member] \| Director Letter Agreement [Member] \| Four Nonemployee [Member]
Stock issued for compensation, shares				2,000,000
Stock based compensation expense		$ 9,419	$ 0	$ 16,448	$ 0
Unvested shares		0		0
Common Stock [Member] \| Consulting Agreement [Member] \| A Consultant [Member]
Stock issued for compensation, shares	1,200,000
Stock based compensation expense		$ 0	$ 0	$ 0	$ 12,816
Unvested shares		0	0	0	0
Common Stock [Member] \| Consulting Agreement [Member] \| A Consultant [Member]
Stock based compensation expense		$ 0	$ 0	$ 0	$ 3,306
Unvested shares		0	0	0	0
Stock to be issued for compensation, shares					500,000
Common Stock [Member] \| Consulting Agreements [Member] \| Two Consultants [Member]
Stock issued for compensation, shares							2,500,000
Stock based compensation expense		$ 0	$ 4,701	$ 0	$ 11,910
Unvested shares		0	0	0	0
Common Stock [Member] \| Consulting Agreements [Member] \| Four Consultants [Member]
Stock issued for compensation, shares				1,000,000
Stock based compensation expense		$ 5,409	$ 0	$ 9,608	$ 0
Unvested shares		500,000		500,000
Common Stock [Member] \| 2019 Compensation Agreement [Member] \| Officers [Member]
Stock issued for compensation, shares					6,600,000
Stock based compensation expense		$ 0	$ 104,727	$ 0	$ 209,453
Unvested shares		0	1,100,000	0	1,100,000
Common Stock [Member] \| Medical And Scientific Advisory Board [Member] \| A Consultant [Member]
Stock issued for compensation, shares					2,000,000
Stock based compensation expense		$ 0	$ 4,701	$ 0	$ 11,851
Unvested shares		0	0	0	0
Common Stock [Member] \| Medical And Scientific Advisory Board [Member] \| A Consultant [Member]
Stock issued for compensation, shares				500,000
Stock based compensation expense		$ 708	$ 0	$ 708	$ 0
Unvested shares		0	0	0	0
Common Stock [Member] \| 2020 Compensation Agreement [Member] \| Officers [Member]
Stock issued for compensation, shares						6,600,000
Stock based compensation expense		$ 67,320		$ 134,640
Unvested shares		1,100,000		1,100,000
Common Stock [Member] \| Four Directors [Member] \| Director Letter Agreement [Member]
Stock issued for compensation, shares					2,000,000
Stock based compensation expense		$ 0	$ 5,408	$ 0	$ 19,212

XML 45 R34.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details - Option Assumptions) - Employee Options [Member]	6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Risk-free interest rate	0.30%	2.00%
Expected volatility	92.00%	91.00%
Expected lives (years)	2 years 6 months	2 years 6 months
Expected dividend yield	0.00%	0.00%

XML 46 R35.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details - Option activity) - Options [Member] - $ / shares	6 Months Ended
	Oct. 31, 2020
Options Outstanding
Beginning balance	67,200,000
Granted	2,000,000
Forfeited
Exercised
Ending balance	69,200,000
Exercisable	67,700,000
Vested and expected to vest	69,200,000
Weighted Average Exercise Price per Share
Beginning balance	$ 0.06
Granted	0.02
Forfeited
Exercised
Ending balance	0.06
Exercisable	0.06
Vested and expected to vest	0.06
Beginning balance	0.06
Granted	0.02
Forfeited
Ending balance	$ 0.06

XML 47 R36.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details - Unvested Option activity) - Unvested Stock Options [Member]	6 Months Ended
	Oct. 31, 2020 $ / shares shares
Options Outstanding
Beginning balance \| shares	6,200,000
Granted \| shares	2,000,000
Vested \| shares	(6,700,000)
Forfeited \| shares
Ending balance \| shares	1,500,000
Beginning balance \| $ / shares	$ 0.05
Granted \| $ / shares	0.02
Vested \| $ / shares
Forfeited \| $ / shares
Ending balance \| $ / shares	$ 0.04

XML 48 R37.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details - Options by exercise price) - $ / shares	6 Months Ended
	Oct. 31, 2020	Apr. 30, 2020
Options [Member]
Number of Options	69,200,000	67,200,000
Weighted Average Remaining Contractual LIfe (years)	1 year 3 months 26 days
Weighted Average Exercisable Price	$ 0.06	$ 0.06
Numer of Options Exercisable	67,700,000
$0.063 [Member]
Number of Options	15,600,000
Weighted Average Remaining Contractual LIfe (years)	1 month 6 days
Weighted Average Exercisable Price	$ 15,600,000
Numer of Options Exercisable	0.063
$0.104 [Member]
Number of Options	10,450,000
Weighted Average Remaining Contractual LIfe (years)	10 months 14 days
Weighted Average Exercisable Price	$ 10,450,000
Numer of Options Exercisable	0.104
$0.0685 [Member]
Number of Options	600,000
Weighted Average Remaining Contractual LIfe (years)	6 months
Weighted Average Exercisable Price	$ 600,000
Numer of Options Exercisable	0.0685
$0.058 [Member]
Number of Options	2,450,000
Weighted Average Remaining Contractual LIfe (years)	1 year 2 months 27 days
Weighted Average Exercisable Price	$ 2,450,000
Numer of Options Exercisable	0.058
$0.0734 [Member]
Number of Options	1,200,000
Weighted Average Remaining Contractual LIfe (years)	10 months 3 days
Weighted Average Exercisable Price	$ 1,200,000
Numer of Options Exercisable	0.0734
$0.0729 [Member]
Number of Options	1,800,000
Weighted Average Remaining Contractual LIfe (years)	1 year 8 months 9 days
Weighted Average Exercisable Price	$ 1,800,000
Numer of Options Exercisable	0.0729
$0.089 [Member]
Number of Options	1,200,000
Weighted Average Remaining Contractual LIfe (years)	1 year 8 months 16 days
Weighted Average Exercisable Price	$ 1,200,000
Numer of Options Exercisable	0.089
$0.0553 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	11 months 19 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.0553
$0.0558 [Member]
Number of Options	9,000,000
Weighted Average Remaining Contractual LIfe (years)	1 year 3 months 19 days
Weighted Average Exercisable Price	$ 9,000,000
Numer of Options Exercisable	0.0558
$0.0534 [Member]
Number of Options	1,200,000
Weighted Average Remaining Contractual LIfe (years)	2 years 10 months 6 days
Weighted Average Exercisable Price	$ 1,200,000
Numer of Options Exercisable	0.0534
$0.0539 [Member]
Number of Options	1,000,000
Weighted Average Remaining Contractual LIfe (years)	1 year 2 months 30 days
Weighted Average Exercisable Price	$ 1,000,000
Numer of Options Exercisable	0.0539
$0.0683 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	1 year 3 months 29 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.0683
$0.0649 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	1 year 5 months 20 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.0649
$0.0495 [Member]
Number of Options	9,000,000
Weighted Average Remaining Contractual LIfe (years)	2 years 11 days
Weighted Average Exercisable Price	$ 9,000,000
Numer of Options Exercisable	0.0495
$0.038 [Member]
Number of Options	1,200,000
Weighted Average Remaining Contractual LIfe (years)	3 years 10 months 25 days
Weighted Average Exercisable Price	$ 1,200,000
Numer of Options Exercisable	0.038
$0.0404 [Member]
Number of Options	1,000,000
Weighted Average Remaining Contractual LIfe (years)	1 year 9 months
Weighted Average Exercisable Price	$ 1,000,000
Numer of Options Exercisable	0.0404
$0.037 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	1 year 9 months 29 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.037
$0.034 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	1 year 11 months 19 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.034
$0.0408 [Member]
Number of Options	9,000,000
Weighted Average Remaining Contractual LIfe (years)	2 years 6 months 3 days
Weighted Average Exercisable Price	$ 7,500,000
Numer of Options Exercisable	0.0408
$0.0240 [Member]
Number of Options	1,000,000
Weighted Average Remaining Contractual LIfe (years)	2 years 2 months 30 days
Weighted Average Exercisable Price	$ 1,000,000
Numer of Options Exercisable	0.024
$0.0247 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	2 years 3 months 29 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.0247
$0.0105 [Member]
Number of Options	500,000
Weighted Average Remaining Contractual LIfe (years)	2 years 5 months 20 days
Weighted Average Exercisable Price	$ 500,000
Numer of Options Exercisable	0.0105

XML 49 R38.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details - Warrant activity) - Warrants [Member]	6 Months Ended
	Oct. 31, 2020 $ / shares shares
Warrants outstanding, beginning balance \| shares	47,890,155
Warrants issued \| shares	34,366,666
Warrants expired \| shares	0
Warrants outstanding, ending balance \| shares	82,256,821
Warrants exercisable \| shares	82,256,821
Weighted average exercise price warrants outstanding, beginning balance \| $ / shares	$ 0.05
Weighted average exercise price warrants issued \| $ / shares	0.01
Weighted average exercise price warrants Expired \| $ / shares
Weighted average exercise price warrants outstanding, ending balance \| $ / shares	0.03
Weighted average exercise price warrants exercisable \| $ / shares	$ 0.03

XML 50 R39.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details - Warrants by exercise price)	6 Months Ended
	Oct. 31, 2020 $ / shares shares
$0.12 [Member]
Number of Warrants exercisable	17,000,000
Weighted Average Remaining Contractual Life (Years)	2 months 8 days
$0.065 [Member]
Number of Warrants exercisable	769,231
Weighted Average Remaining Contractual Life (Years)	1 year 1 month 16 days
$0.0575 [Member]
Number of Warrants exercisable	869,565
Weighted Average Remaining Contractual Life (Years)	1 year 5 months 1 day
$0.03 [Member]
Number of Warrants exercisable	2,500,000
Weighted Average Remaining Contractual Life (Years)	2 years 26 days
$0.026 [Member]
Number of Warrants exercisable	1,923,077
Weighted Average Remaining Contractual Life (Years)	2 years 7 months 28 days
$0.025 [Member]
Number of Warrants exercisable	2,000,000
Weighted Average Remaining Contractual Life (Years)	1 year 8 months 23 days
$0.018 [Member]
Number of Warrants exercisable	1,388,889
Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
$0.011 [Member]
Number of Warrants exercisable	2,272,727
Weighted Average Remaining Contractual Life (Years)	3 years
$0.01 [Member]
Number of Warrants exercisable	13,200,000
Weighted Average Remaining Contractual Life (Years)	4 years 5 months 1 day
$0.015 [Member]
Number of Warrants exercisable	833,333
Weighted Average Remaining Contractual Life (Years)	4 years 5 months 20 days
$0.009 [Member]
Number of Warrants exercisable	3,333,333
Weighted Average Remaining Contractual Life (Years)	3 years 8 months 2 days
$0.0075 [Member]
Number of Warrants exercisable	15,666,666
Weighted Average Remaining Contractual Life (Years)	4 years 8 months 26 days
$0.005 [Member]
Number of Warrants exercisable	20,500,000
Weighted Average Remaining Contractual Life (Years)	4 years 1 month 16 days
Warrants [Member]
Number of Warrants exercisable	82,256,821
Weighted Average Remaining Contractual Life (Years)	3 years 3 months 11 days
Weighted average exercise price exercisable \| $ / shares	$ 0.03

XML 51 R40.htm IDEA: XBRL DOCUMENT

6. STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended		3 Months Ended										6 Months Ended
	Jun. 13, 2019	Jul. 10, 2020	Jul. 15, 2019	Oct. 31, 2020	Aug. 10, 2020	Aug. 07, 2020	Aug. 06, 2020	Aug. 03, 2020	Jul. 27, 2020	Jul. 19, 2020	Jul. 18, 2020	Oct. 31, 2019	Aug. 07, 2019	Oct. 31, 2020	Oct. 31, 2019	Apr. 30, 2020
Stock based compensation - options														$ 128,376	$ 224,734
Stock price per share				$ 0.0089										$ 0.0089
Options [Member]
Options outstanding				69,200,000										69,200,000		67,200,000
Options granted in period														2,000,000
Aggregate intrinsic value				$ 0										$ 0
Options [Member] \| Employees [Member]
Options granted in period														2,000,000	2,000,000
Stock based compensation - options				56,059								$ 93,995		$ 128,376	$ 210,909
Unrecognized compensation expense				$ 35,410										$ 35,410
Options [Member] \| Non-Employees [Member]
Options granted in period				0								1,200,000		0	1,200,000
Stock based compensation - options				$ 0								$ 4,414		$ 0	$ 13,825
Unrecognized compensation expense weighted-average period														2 months
Warrants [Member] \| Aeon [Member]
Warrants issued	1,338,889	4,100,000	1,944,444		1,333,333	2,500,000	4,100,000	4,500,000	2,500,000	1,333,333	3,500,000		3,500,000
Aggregate fair value of warrants issued	$ 9,000	$ 29,000	$ 12,000		$ 7,000	$ 13,000	$ 29,000	$ 24,000	$ 13,000	$ 7,000	$ 18,000		$ 12,000
Warrants [Member] \| Aeon [Member]
Warrants issued						5,500,000	5,000,000
Aggregate fair value of warrants issued						$ 19,000	$ 18,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

8. RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
SG Austria [Member]
Equity interest owned	14.50%		14.50%
SG Austria [Member]
Purchases from related parties	$ 10,000	$ 0	$ 74,000	$ 2,400
Vin-de-Bona [Member]
Consulting fees	$ 21,000	$ 2,000	44,000	$ 15,000
Share base compensation expense			$ 2,300
Vin-de-Bona [Member] \| Dr. Salmons [Member]
Stock issued for services, shares			250,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

9. COMMITMENTS AND CONTINGENCIES (Details)	Oct. 31, 2020 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Minimum operating lease expense 2021	$ 5,144
Minimum operating lease expense	$ 5,144

XML 54 R43.htm IDEA: XBRL DOCUMENT

9. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Rent and lease expense	$ 5,384	$ 7,999	$ 12,536	$ 16,660

XML 55 R44.htm IDEA: XBRL DOCUMENT

10. INCOME TAXES (Details Narrative) - USD ($)	6 Months Ended
10. INCOME TAXES (Details Narrative) - USD ($)	Oct. 31, 2020	Oct. 31, 2019	Apr. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0
Increase in valuation allowance	355,000	$ 449,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 0		$ 0

XML 56 R45.htm IDEA: XBRL DOCUMENT

11. EARNINGS PER SHARE (Details - per share calculation) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (950,192)	$ (1,067,122)	$ (1,834,136)	$ (2,201,197)
Basic weighted average number of shares outstanding	2,309,218,013	1,325,086,933	1,993,895,090	1,267,696,383
Diluted weighted average number of shares outstanding	2,309,218,013	1,325,086,933	1,993,895,090	1,267,696,383
Basic and diluted loss per share	$ 0.00	$ 0.00	$ 0.00	$ 0.00

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 57 R46.htm IDEA: XBRL DOCUMENT

11. EARNINGS PER SHARE (Details - diluted shares) - shares	6 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Antidilutive shares	151,456,821	133,706,822
Options [Member]
Antidilutive shares	69,200,000	85,650,000
Warrants [Member]
Antidilutive shares	82,256,821	48,056,822

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 254 277 1 false 78 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://pharmacyte.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://pharmacyte.com/role/ConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://pharmacyte.com/role/ConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://pharmacyte.com/role/ConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) Sheet http://pharmacyte.com/role/ConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://pharmacyte.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://pharmacyte.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://pharmacyte.com/role/ConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 8 false false R9.htm 00000009 - Disclosure - 1. NATURE OF BUSINESS Sheet http://pharmacyte.com/role/NatureOfBusiness 1. NATURE OF BUSINESS Notes 9 false false R10.htm 00000010 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - 3. ACCRUED EXPENSES Sheet http://pharmacyte.com/role/AccruedExpenses 3. ACCRUED EXPENSES Notes 11 false false R12.htm 00000012 - Disclosure - 4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM Sheet http://pharmacyte.com/role/SmallBusinessAdministration-PaycheckProtectionProgram 4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM Notes 12 false false R13.htm 00000013 - Disclosure - 5. COMMON STOCK TRANSACTIONS Sheet http://pharmacyte.com/role/CommonStockTransactions 5. COMMON STOCK TRANSACTIONS Notes 13 false false R14.htm 00000014 - Disclosure - 6. STOCK OPTIONS AND WARRANTS Sheet http://pharmacyte.com/role/StockOptionsAndWarrants 6. STOCK OPTIONS AND WARRANTS Notes 14 false false R15.htm 00000015 - Disclosure - 7. LEGAL PROCEEDINGS Sheet http://pharmacyte.com/role/LegalProceedings 7. LEGAL PROCEEDINGS Notes 15 false false R16.htm 00000016 - Disclosure - 8. RELATED PARTY TRANSACTIONS Sheet http://pharmacyte.com/role/RelatedPartyTransactions 8. RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES Sheet http://pharmacyte.com/role/CommitmentsAndContingencies 9. COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 00000018 - Disclosure - 10. INCOME TAXES Sheet http://pharmacyte.com/role/IncomeTaxes 10. INCOME TAXES Notes 18 false false R19.htm 00000019 - Disclosure - 11. EARNINGS PER SHARE Sheet http://pharmacyte.com/role/EarningsPerShare 11. EARNINGS PER SHARE Notes 19 false false R20.htm 00000020 - Disclosure - 12. PREFERRED STOCK Sheet http://pharmacyte.com/role/PreferredStock 12. PREFERRED STOCK Notes 20 false false R21.htm 00000021 - Disclosure - 13. SUBSEQUENT EVENTS Sheet http://pharmacyte.com/role/SubsequentEvents 13. SUBSEQUENT EVENTS Notes 21 false false R22.htm 00000022 - Disclosure - 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 00000023 - Disclosure - 3. ACCRUED EXPENSES (Tables) Sheet http://pharmacyte.com/role/AccruedExpensesTables 3. ACCRUED EXPENSES (Tables) Tables http://pharmacyte.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - 5. COMMON STOCK TRANSACTIONS (Tables) Sheet http://pharmacyte.com/role/CommonStockTransactionsTables 5. COMMON STOCK TRANSACTIONS (Tables) Tables http://pharmacyte.com/role/CommonStockTransactions 24 false false R25.htm 00000025 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Tables) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsTables 6. STOCK OPTIONS AND WARRANTS (Tables) Tables http://pharmacyte.com/role/StockOptionsAndWarrants 25 false false R26.htm 00000026 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://pharmacyte.com/role/CommitmentsAndContingenciesTables 9. COMMITMENTS AND CONTINGENCIES (Tables) Tables http://pharmacyte.com/role/CommitmentsAndContingencies 26 false false R27.htm 00000027 - Disclosure - 11. EARNINGS PER SHARE (Tables) Sheet http://pharmacyte.com/role/EarningsPerShareTables 11. EARNINGS PER SHARE (Tables) Tables http://pharmacyte.com/role/EarningsPerShare 27 false false R28.htm 00000028 - Disclosure - 2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://pharmacyte.com/role/SignificantAccountingPoliciesDetailsNarrative 2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details 28 false false R29.htm 00000029 - Disclosure - 3. ACCRUED EXPENSES (Details) Sheet http://pharmacyte.com/role/AccruedExpensesDetails 3. ACCRUED EXPENSES (Details) Details http://pharmacyte.com/role/AccruedExpensesTables 29 false false R30.htm 00000030 - Disclosure - 3. ACCRUED EXPENSES (Details Narrative) Sheet http://pharmacyte.com/role/AccruedExpensesDetailsNarrative 3. ACCRUED EXPENSES (Details Narrative) Details http://pharmacyte.com/role/AccruedExpensesTables 30 false false R31.htm 00000031 - Disclosure - 4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM (Details Narrative) Sheet http://pharmacyte.com/role/SmallBusinessAdministration-PaycheckProtectionProgramDetailsNarrative 4. SMALL BUSINESS ADMINISTRATION - PAYCHECK PROTECTION PROGRAM (Details Narrative) Details http://pharmacyte.com/role/SmallBusinessAdministration-PaycheckProtectionProgram 31 false false R32.htm 00000032 - Disclosure - 5. COMMON STOCK TRANSACTIONS (Details - Nonvested Option activity) Sheet http://pharmacyte.com/role/CommonStockTransactionsDetails-NonvestedOptionActivity 5. COMMON STOCK TRANSACTIONS (Details - Nonvested Option activity) Details http://pharmacyte.com/role/CommonStockTransactionsTables 32 false false R33.htm 00000033 - Disclosure - 5. COMMON STOCK TRANSACTIONS (Details Narrative) Sheet http://pharmacyte.com/role/CommonStockTransactionsDetailsNarrative 5. COMMON STOCK TRANSACTIONS (Details Narrative) Details http://pharmacyte.com/role/CommonStockTransactionsTables 33 false false R34.htm 00000034 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Option Assumptions) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionAssumptions 6. STOCK OPTIONS AND WARRANTS (Details - Option Assumptions) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 34 false false R35.htm 00000035 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Option activity) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity 6. STOCK OPTIONS AND WARRANTS (Details - Option activity) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 35 false false R36.htm 00000036 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Unvested Option activity) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-NonvestedOptionActivity 6. STOCK OPTIONS AND WARRANTS (Details - Unvested Option activity) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 36 false false R37.htm 00000037 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Options by exercise price) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionsByExercisePrice 6. STOCK OPTIONS AND WARRANTS (Details - Options by exercise price) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 37 false false R38.htm 00000038 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Warrant activity) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity 6. STOCK OPTIONS AND WARRANTS (Details - Warrant activity) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 38 false false R39.htm 00000039 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details - Warrants by exercise price) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantsByExercisePrice 6. STOCK OPTIONS AND WARRANTS (Details - Warrants by exercise price) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 39 false false R40.htm 00000040 - Disclosure - 6. STOCK OPTIONS AND WARRANTS (Details Narrative) Sheet http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative 6. STOCK OPTIONS AND WARRANTS (Details Narrative) Details http://pharmacyte.com/role/StockOptionsAndWarrantsTables 40 false false R41.htm 00000041 - Disclosure - 8. RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://pharmacyte.com/role/RelatedPartyTransactionsDetailsNarrative 8. RELATED PARTY TRANSACTIONS (Details Narrative) Details http://pharmacyte.com/role/RelatedPartyTransactions 41 false false R42.htm 00000042 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Details) Sheet http://pharmacyte.com/role/CommitmentsAndContingenciesDetails 9. COMMITMENTS AND CONTINGENCIES (Details) Details http://pharmacyte.com/role/CommitmentsAndContingenciesTables 42 false false R43.htm 00000043 - Disclosure - 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://pharmacyte.com/role/CommitmentsAndContingenciesTables 43 false false R44.htm 00000044 - Disclosure - 10. INCOME TAXES (Details Narrative) Sheet http://pharmacyte.com/role/IncomeTaxesDetailsNarrative 10. INCOME TAXES (Details Narrative) Details http://pharmacyte.com/role/IncomeTaxes 44 false false R45.htm 00000045 - Disclosure - 11. EARNINGS PER SHARE (Details - per share calculation) Sheet http://pharmacyte.com/role/EarningsPerShareDetails 11. EARNINGS PER SHARE (Details - per share calculation) Details http://pharmacyte.com/role/EarningsPerShareTables 45 false false R46.htm 00000046 - Disclosure - 11. EARNINGS PER SHARE (Details - diluted shares) Sheet http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares 11. EARNINGS PER SHARE (Details - diluted shares) Details http://pharmacyte.com/role/EarningsPerShareTables 46 false false All Reports Book All Reports pmcb-20201031.xml pmcb-20201031.xsd pmcb-20201031_cal.xml pmcb-20201031_def.xml pmcb-20201031_lab.xml pmcb-20201031_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 63 0001683168-20-004267-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-20-004267-xbrl.zip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end